Published Ahead of Print on October 18, 2022 as 10.1212/WNL.0000000000201426

Neurology®
The most widely read and highly cited peer-reviewed neurology journal
The Official Journal of the American Academy of Neurology

AMERICAN ACADEMY OF NEUROLOGY®

Neurology Publish Ahead of Print
DOI: 10.1212/WNL.0000000000201426

Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events: One-Year Follow-up

Author(s):
Thanh N. Nguyen, MD, FRCPC[1,2]; Muhammad M Qureshi, MBBS, MPH[2,3]; Piers Klein, MA[1,2]; Hiroshi Yamagami, MD, PhD[4]; Robert Mikulik, MD, PhD[5]; Anna Czlonkowska, MD, PhD[6]; Mohamad Abdalkader, MD[2]; Petra Sedova, MD, PhD[5,7]; Anvitha Sathya[1,2]; Hannah C. Lo, BS[1,2]; Ossama Yassin Mansour, MD, PhD[8]; Husitha Reddy Vanguru, MD[9]; Emilie Lesaine, MD[10]; Georgios Tsivgoulis, MD, PhD[11]; Aaron I. Loochtan, DO[12]; Jelle Demeestere, MD[13]; Ken Uchino, MD[9]; Violiza Inoa, MD[14]; Nitin Goyal, MD[14]; Andreas Charidimou, MD, PhD[1]; James E. Siegler[15]; Shadi Yaghi, MD[16]; Diana Aguiar de Sousa, MD, PhD[17,18]; Mahmoud Mohammaden, MD[19]; Diogo C Haussen, MD[19]; Espen Saxhaug Kristoffersen, MD, PhD[20]; Virginia Pujol Lereis, MD[21]; Sergio Daniel Scollo, MD[22]; Bruce C. V. Campbell, MBBS PhD[23]; Alice Ma, MD[24]; James Orton Thomas, B.Med[25]; Mark W Parsons, PhD[26]; Shaloo Singhal, MBBS[27]; Lee-Anne Slater, MBBS, FRANZCR Mmed[27]; Rodrigo Tomazini Martins, MD, PhD[28]; Chris Enzinger, MD[29]; Thomas Gattringer, MD[30]; Aminur Rahman, MD, FCPS[31]; Thomas Bonnet, MD[32]; Noemie Ligot, MD[32]; Sylvie De Raedt, MD PhD[33]; Robin Lemmens, MD[13]; Peter Vanacker, MD[34]; Fenne Vandervorst, MD[33]; Adriana Bastos Conforto, MD, PhD[35]; Raquel C.T. Hidalgo, MD[36]; Luciana de Oliveira Neves, MD[37]; Rodrigo Targa Martins, MD[38]; Daissy Liliana Mora Cuervo, MD[39]; Leticia C. Rebello, MD[40]; Igor Bessa Santiago, MD[37]; Isabelle Lameirinhas da Silva, MD[35]; Teodora Sakelarova, MD[41]; Rosen Kalpachki, MD[41]; Filip Alexiev, MD[41]; Luciana Catanese, MD[42]; Elena Adela Cora, MD, PhD[43]; Mayank Goyal, MD PhD FRCPC[44]; Michael D. Hill, MD MSc FRCPC[44]; Michael E. Kelly, MD, PhD[45]; Houman Khosravani, MD, PhD[46]; Pascale Lavoie, MD[47]; Lissa Peeling, MD[45]; Aleksandra Pikula, MD[48]; Rodrigo Rivera, MD[49]; Hui-Sheng Chen, MD[50]; Yimin Chen, MD[51]; Xiaochuan Huo, MD[52]; Zhongrong Miao, MD[52]; Shuiquan Yang, MD[51]; Marina Roje Bedekovic, MD[53]; Marina Bralic, MD, PhD[54]; Hrvoje Budincevic, MD, PhD[55]; Angel Basilio Corredor-Quintero, MD[56]; Osvaldo E. Lara-Sarabia, MD, MSc[57]; Martin Cabal, MD[58]; Dusan Tenora, MD[59]; Petr Fibrich, MD[60]; Roman Herzig, MD, PhD[61]; Helena Hlaváčová, MD[62]; Emanuela Hrabanovska, MD[63]; David Hlinovsky, MD[64]; Lubomir Jurak, MD, PhD[65]; Jana Kadlcikova, MD[66]; Igor Karpowicz, MD[67]; Lukas Klecka, MD[68]; Martin Kovar, MD[69]; David Lauer, MD[70]; Jiri Neumann, MD, FESO[71]; Hana Palouskova, MD[72]; Martin Reiser, MD[73]; Petra Rekova, MD[74]; Vladimir Rohan, MD[75]; Ondrej Skoda, MD[76]; Miroslav Škorňa, MD[77]; Lenka Sobotková, MD[78]; Martin Sramek, MD[79]; Lenka Zakova, MD[80]; Hanne Christensen, MD, PhD[81]; Nicolas Drenck, MD[81]; Helle Klingenberg Iversen, MD[82]; Thomas Clement Truelsen, MD[82]; Troels Wienecke, MD[83]; Khalid Sobh, MD[84]; Pauli Ylikotila, MD, MSc[85]; Kemal Alpay, MD[86]; Daniel Strbian, MD[87]; Patricia Bernady, MD[88]; Philippe Casenave, MD[89]; Maria Dan, MD[90]; Jean-Marc Faucheux, MD[91]; Jean-Christophe Gentric, MD[92]; Elsa Magro, MD[93]; Candice Sabben, MD[94]; Peggy Reiner, MD[95]; Francois Rouanet, MD[96]; Ferdinand O. Bohmann, MD[97]; Stefan Boskamp, MD[98]; Joshua Mbroh, MD, MSc[99,100]; Simon Nagel, MD[101,102]; Christian Nolte[103]; Peter A. Ringleb, MD[102]; Michael Rosenkranz, MD[98]; Sven Poli, MD, MSc[99,100]; Götz Thomalla, MD[104]; Theodoros Karapanayiotides, MD, PhD[105]; Ioanna Koutroulou, MD, PhD[105]; Odysseas Kargiotis, MD[106]; Lina Palaiodimou, MD[11]; Jose Dominguo Barrientos Guerra, MD[107]; Vikram Huded, MD[108]; Bindu Menon, MD[109]; Shashank Nagendra, MD[110]; Chintan Prajapati, MD[111]; P.N. Sylaja, MBBS, MD, DM[112]; Nyoman Angga Krishna Pramana, MD[113]; Achmad Firdaus Sani, MD[114]; Abdoreza Ghoreishi, MD[115]; Mehdi Farhoudi, MD[116]; Elyar Sadeghi Hokmabadi, MD[116]; Tariq Abu Raya, MD[117]; Shani Avnery Kalmanovich, MD[118]; Levite Ronen, MD[118]; Sergiu Ionut Sabetay, MD[117]; Maurizio Acampa, MD, PhD[119]; Alessandro Adami, MD[120]; Lucio Castellan, MD[121]; Marco Longoni, MD[122]; Raffaele Ornello, MD, PhD[123]; Leonardo Renieri, MD[124]; Claudia Rolla Bigliani, MD[121]; Michele Romoli, MD, PhD[122]; Simona Sacco, MD[123]; Andrea Salmaggi, MD[125]; Davide Sangalli, MD[125]; Andrea Zini[126]; Ryosuke Doijiri, MD[127]; Hiroki Fukuda, MD[128]; Toshiyuki Fujinaka, MD[129]; Kyohei Fujita, MD[130]; Hirotoshi Imamura, MD[131]; Nobuyuki Sakai, MD[131]; Takuya Kanamaru, MD[132]; Naoto Kimura, MD[133]; Ryuhei Kono, MD[134]; Kosuke Miyake, MD[135]; Manabu Sakaguchi, MD[136]; Kenichiro Sakai, MD[137]; Kazutaka Sonoda, MD[138]; Kenichi Todo, MD, PhD[139]; Fumio Miyashita, MD[140]; Naoki Tokuda, MD[141]; Yuji Matsumaru, MD[142]; Shoji Matsumoto, MD[143]; Nobuyuki Ohara, MD[144]; Seigo Shindo, MD[145]; Yohei Takenobu, MD[146]; Takeshi Yoshimoto, MD[147]; Kazunori Toyoda, M.D., Ph.D.[148]; Takeshi Uwatoko, MD[149]; Yoshiki Yagita, MD[150]; Takehiro Yamada, MD[151]; Nobuaki Yamamoto, MD[152]; Ryoo Yamamoto, MD[153]; Yukako Yazawa, MD[154]; Yuri Sugiura, MD[155];

Peter Kuria Waweru, MBChB, MSc[156]; Jang-Hyun Baek, MD[157]; Si Baek Lee, MD[158]; Kwon-Duk Seo, MD[159]; Sung-Il Sohn, MD[160]; Anita Ante Arsovska, MD, PhD[161]; Yong Chieh Chan, MD[162]; Wan Asyraf Wan Zaidi, Mmed[163]; Ainul Syahrilfazli Jaafar, MD[164]; Fernando Gongora-Rivera, MD, PhD[165]; Manuel Martinez-Marino, MD, MSc[166]; Adrian Infante-Valenzuela, MD[167]; Stanislav Groppa, MD, PhD[168]; Pavel Leahu, 168[168]; Jonathan M. Coutinho, MD, PhD[169]; Leon A. Rinkel, MD[169]; Diederik W.J. Dippel, MD, PhD[170]; Dianne H.K. van Dam-Nolen, MD[170]; Annemarei Ranta, MD, PhD, FRACP[171]; Teddy Y Wu, PhD[172]; Tajudeen Temitayo Adebayo[173]; Abiodun H. Bello[174]; Ernest Okwundu Nwazor, MBBS[175]; Taofiki Ajao Sunmonu, MD[176]; Kolawole Wasiu Wahab, MD[177]; Ole Morten Ronning, MD, PhD[178]; Else Charlotte Sandset, MD[179]; Amal M. Al Hashimi, MD[180]; Saima Ahmad, MBBS[181]; Umair Rashid, MD[181]; Liliana Rodriguez-Kadota, MD[182]; Miguel Ángel Vences, MD[182]; Patrick Matic Yalung, MD[183]; Jon Stewart Hao Dy, MD[184]; Maria Carissa Pineda-Franks, MD[184]; Christian Oliver Co, MD[184]; Waldemar Brola, MD, PhD[185]; Aleksander Debiec, MD[186]; Malgorzata Dorobek, MD, PhD[187]; Michal Adam Karlinski, MD, PhD[6]; Beata M. Labuz-Roszak, MD, PhD[188]; Anetta Lasek-Bal, MD, PhD[189]; Halina Sienkiewicz-Jarosz, MD[190]; Jacek Staszewski, MD, PhD[191]; Piotr Sobolewski, MD[192]; Marcin Wiacek, MD[193]; Justyna Zielinska-Turek, MD[194]; Andre Pinho Araujo, MD[195]; Mariana Rocha, MD[196]; Pedro Castro, MD, PhD[197]; Vitor Tedim Cruz, MD, PhD[198]; Paulo Venancio Ferreira, MD[198]; Patricia Ferreira, MD[199]; Ana Paiva Nunes, MD[199]; Luisa Fonseca, MD[200]; João Pedro Marto, MD[201]; Teresa Pinho e Melo, MD[202]; Miguel Rodrigues, MD[203]; M Luis Silva, MD[204]; Adela Dimitriade, MD[205]; Cristian Falup-Pecurariu, MD, PhD[206]; May Adel Hamid, MD[207]; Narayanaswamy Venketasubramanian, FRCP[208]; Georgi Krastev, MD, PhD[209,210]; Miroslav Mako, MD[209]; Oscar Ayo-Martin, MD, PhD[211]; Francisco Hernández-Fernández, MD, PhD[211]; Jordi Blasco, MD, PhD[212]; Alejandro Rodríguez-Vázquez, MD[213]; Antonio Cruz-Culebras, MD[214]; Francisco Moniche, MD, PhD[215]; Joan Montaner, MD, PhD[216]; Soledad Perez-Sanchez, MD[216]; María Jesús García Sánchez, MD[217]; Marta Guillán Rodríguez, MD[218]; Katarina Jood, MD[219,220]; Annika Nordanstig, MD, PhD[219,220]; Michael V. Mazya, MD, PhD[221]; Tiago T.P. Moreira, MD, PhD[221]; Gianmarco Bernava, MD[222]; Morin Beyeler, MD[223]; Manuel Bolognese, MD[224]; Emmanuel Carrera, MD[225]; Tomas Dobrocky, MD[226]; Grzegorz Marek Karwacki, MD[227]; Emanuela Keller, MD[228]; Chang Yang Hsieh, MD[229]; Surawan Boonyakarnkul, MD[230]; Anchalee Churojana, MD[231]; Ozlem Aykac, MD[232]; Atilla & Ozdemir, MD[232]; Arsida Bajrami, MD[233]; Songul Senadim, MD[233]; Syed Irteza Hussain, MD[234]; Seby John, MD[234]; Soma Banerjee, MD[235]; Joseph Kwan, MD[235]; Kailash Krishnan, MD[236]; Robert Lenthall, MD[237]; Ashok Matthews, MD[238]; Ken Wong, MD[239]; Liqun Zhang, MD, PhD[240]; Dorothea Altschul, MD[241]; Kaiz S. Asif, MD[242]; Zeelalem Bahiru, NP[243]; Kristine Below, BS[244]; José Biller, MD, FACP, FAAN, FANA, FAHA[245]; Sean Ruland, DO[245]; Saqib A. Chaudry, MD[246]; Michael Chen, MD[247]; Alex Chebl, MD[248]; Jackie Cibulka, RN[249]; Leon Cistrunk[250]; Judith Clark, RN[1]; Marco Colasurdo, MD[251]; Alexandra Czap, MD[252]; Adam de Havenon, MD[253]; Salvatore D'Amato, MD[254]; Sushrut Dharmadhikari, MD[255]; Kasey B. Grimmett, BSN, RN[255]; Adam A Dmytriw, MD, MPH[254,256]; Mark R Etherton, MD, PhD[257]; Chizoba Ezepue, MD[258]; Mudassir Farooqui, MD, MPH[259]; Steven K. Feske, MD[1]; Lauren Fink, BSN, RN[260]; Ulviyya Gasimova, MD[261]; Amy K. Guzik, MD[262]; Maryam Hakemi, BSN, MS, AGNP[263]; Majesta Hovingh, MD[264]; Muhib Khan, MD[264]; Dinesh Jillela, MD[265]; Peter T. Kan, MD, MPH[266]; Rakesh Khatri, MD[267]; Ayaz M. Khawaja, MD[263]; Naim N. Khoury, MD[268]; Nicole L. Kiley, PA-C[2]; Benny S. Kim, MD[269]; Murali K. Kolikonda, MD[270]; Anna Luisa Kuhn, MD, PhD[271]; Stephanie Lara, RN, MS-HCA, SCRN[272]; Guillermo Linares, MD[273]; Italo Linfante, MD[274]; Timothy G. Lukovits, MD[275]; Sarah Lycan, NP[262]; Shailesh S. Male, MD[277]; Laith Maali, MD[278]; John Mancin, DO[279]; Hesham Masoud, MD[280]; Ghada A. Mohamed, MD, MSc[281]; Andre Monteiro, MD[282]; Fadi Nahab, MD[283]; Krishna Nalleballe, MD[284]; Santiago Ortega Gutierrez, MD MS[259]; Ajit S. Puri, MD[271]; Yazan Radaideh, MD[247]; Rahul H. Rahangdale, MD[285]; Ansaar Rai, MD[279]; Pankajavalli Ramakrishnan, MD, PhD[286]; Aravind B. Reddy, MD[280]; Diana M. Rojas-Soto, MD[275]; Jose Rafael Romero, MD[1]; Natalia S Rost, MD, MPH[257]; Aaron Rothstein, MD[287]; Setareh Salehi Omran, MD[288]; Sunil A. Sheth, MD[252]; Adnan H. Siddiqui, MD, PhD[282]; Amy K. Starosciak, PhD[289]; Nicholas E. Tarlov, MD[272]; Robert A. Taylor, MD[260]; Michael J. Wang, MD[290]; Jared Wolfe, BA[15]; Ka-Ho Wong, MBA[291]; Huynh Vu Le, MD[292]; Quy Viet Nguyen, MD[292]; Thong Nhu Pham, MD[293]; Trung Thanh Nguyen, MD[293]; Hoang Thi Phan, MD[294]; Mai Duy Ton, MD[294]; Urs Fischer[223,295]; Patrik Michel, M.D., Ph.D[296]; Davide

Strambo, MD[296]; Sheila O. Martins, MD, PhD[297]; Osama O. Zaidat, MD[244]; Raul G Nogueira, MD[298] on behalf of and the SVIN COVID-19 Global Stroke Registry

Corresponding Author:
Thanh N. Nguyen, thanh.nguyen@bmc.org

Affiliation Information for All Authors: 1. Department of Neurology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine; 2. Department of Radiology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine; 3. Department of Radiation Oncology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine; 4. Department of Stroke Neurology, National Hospital Organization, Osaka National Hospital, Japan; 5. Department of Neurology, International Clinical Research Centre, St Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic; 6. 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland; 7. Department of Internal Medicine and Cardiology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; 8. Department of Neurology, Alexandria University Stroke and Neurointervention Unit, Alexandria, Egypt; 9. Department of Neurology, Cleveland Clinic, USA; 10. Centre Hospitalier de l'Université de Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France; 11. Second Department of Neurology, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece; 12. Ohio Health Riverside Methodist Hospital, USA; 13. Neurology Department, Leuven University Hospital, Leuven, Belgium; 14. University of Tennessee Health Science Center, Tennessee, USA; 15. Cooper Neurological Institute, Cooper University Hospital, Camden, NJ, USA; 16. Department of Neurology, Rhode Island Hospital, Brown University, Providence, Rhode Island; 17. Stroke Center, Centro Hospitalar Universitário Lisboa Central – CHULC, Portugal, CEEM; 18. Institute of Anatomy, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; 19. Department of Neurology, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, USA; 20. Department of Neurology, Akershus University Hospital, University of Oslo, Oslo, Norway and Department of General Practice, University of Oslo, Norway; 21. Division de Neurologia Vascular, Departmento de Neurologia, Institute for Neurological Research - FLENI, Buenos Aires, Argentina; 22. Stroke Unit, Ramos Mejia Hospital, Buenos Aires, Argentina; 23. Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia; 24. Royal North Shore Hospital, Sydney, Australia; 25. Department of Neurophysiology, Liverpool Hospital, New South Wales, Australia; 26. Department of Neurology, Liverpool Hospital, New South Wales, Australia; 27. Monash University, Melbourne, Australia; 28. Department of Neurology, Mater Hospital, Brisbane, Australia; 29. Department of Neurology, Medical University of Graz, Graz, Austria; 30. Department of Neurology and Division of Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, Graz, Austria; 31. Department of Neurology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh; 32. Hopital Erasme, Brussels, Belgium; 33. Department of Neurology, Universitair Ziekenhuis Brussel, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium; 34. Department of Neurology, University Hospitals Antwerp; Department of Translational Neuroscience, University of Antwerp, Belgium; 35. Hospital das Clínicas, São Paulo University, Brazil; 36. Department of Neurology and Interventional Neuroradiology, Hospital de Base de São José do Rio Preto, São Paulo, Brazil; 37. Hospital São Carlos, Brazil; 38. Stroke Unit, Neurology, Nossa Senhora da Conceição Hospital, Porto Alegre, Brazil; 39. Moinhos de Vento Hospital, Brazil; 40. Hospital de Base do Distrito Federal, Brasilia, Brazil; 41. St. Anna University Hospital, Sofia, Bulgaria; 42. Department of Neurology, McMaster University, Hamilton, Canada; 43. Department of Diagnostic Radiology, Halifax Infirmary, Dalhousie University, Halifax, Canada; 44. Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cummings School of Medicine, University of Calgary, Canada; 45. Royal University Hospital, Saskatoon, Saskatchewan, Canada; 46.

Department of Neurology, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Division of Neurology, Department of Medicine, University of Toronto, Canada; 47. Hopital Enfant Jesus, Centre Hospitalier de l'Université Laval, Quebec City, Canada; 48. Toronto Western Hospital, University of Toronto, Toronto, Canada; 49. Neuroradiology Department, Instituto de Neurocirugía Dr. Asenjo, Santiago, Chile; 50. Department of Neurology, General Hospital of Northern Theater Command, Shen Yang, China; 51. Department of Neurology, Foshan Sanshui District People's Hospital, China; 52. Interventional Neuroradiology, Beijing Tiantian Hospital, Beijing, China; 53. Department of Neurology, Sestre Milosrdnice University Hospital Center, Croatia; 54. Department of Neurology, Clinical Hospital Center Rijeka, Rijeka, Croatia; 55. Sveti Duh University Hospital - Zagreb, Department of Neurology, Zagreb, Croatia; J.J. Strossmayer University of Osijek, Faculty of Medicine, Department of Neurology and Neurosurgery, Osijek, Croatia; 56. Department of Neurology, Hospital Departamental Universitario del Quindío San Juan de Dios, Colombia; 57. Department of Neurology, Clínica de la Costa, Barranquilla, Colombia; 58. Department of Neurology, Faculty Hospital Ostrava, Czech Republic; 59. Department of Neurology, Blansko Hospital, Czech Republic; 60. Oblastní nemocnice Trutnov a.s., Czech Republic; 61. Department of Neurology, Comprehensive Stroke Center, Charles University Faculty of Medicine and University Hospital, Czech Republic; 62. Neurology, Hospital Příbram, Czech Republic; 63. Uherskohradišťská Hospital, Czech Republic; 64. Department of Neurology, Thomayer University Hospital Prague, Czech Republic; 65. Neurocenter, Regional Hospital Liberec, Czech Republic; 66. Neurology, Hospital Vyskov, Czech Republic; 67. Regional Hospital Karlovy Vary, Czech Republic; 68. Ostrava, Czech Republic; 69. Na Homolce Hospital, Czech Republic; 70. Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Czech Republic; 71. Department of Neurology, Krajská zdravotní, a.s. - Hospital Chomutov, Chomutov, Czech Republic; 72. Karvina Mining Hospital, Czech Republic; 73. Neurology, České Budejovice Hospital, České Budějovice, Czech Republic; 74. Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; 75. Department of Neurology, University Hospital Plzen, Czech Republic; 76. Department of Neurology, Hospital Jihlava, Czech Republic; 77. Department of Neurology, Masaryk University Faculty of Medicine, University Hospital Brno, Brno, Czech Republic 78. Oblastni nemocnice Kladno, Czech Republic; 79. Central Military Hospital in Prague, Czech Republic; 80. Nemocnice Třinec, Czech Republic; 81. Copenhagen University Hospital, Copenhagen, Denmark; 82. Stroke Center, Rigshospitalet, University of Copenhagen, Denmark; 83. Neurovascular Center, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark; 84. El hussein Alzahar University Hospital, Egypt; 85. Neurocenter, Turku University Hospital, Turku University, Turku, Finland; 86. Department of Radiology, Turku University Hospital, Turku, Finland; 87. Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; 88. Bayonne Hospital Neurology, Stroke Unit, Bayonne, France; 89. Libourne Hospital Neurology, Stroke Unit, Libourne, France; 90. Centre Hospitalier d'Arcachon - Neurologie, Arcachon, France; 91. Agen Hospital Neurology, Stroke Unit, Agen, France; 92. Neuroradiologie Interventionelle, Brest University Hospital, Brest, France; 93. Neurochirurgie, Brest University Hospital, Brest, France; 94. Department of Neurology, Rothschild Foundation Hospital, Paris, France; 95. Lariboisiere Hospital, Paris, France; 96. Bordeaux University Hospital Neurology, Stroke Unit, Bordeaux, France; 97. Department of Neurology, University Hospital/ Goethe University, Frankfurt, Germany; 98. Department of Neurology, Albertinen Krankenhaus, Hamburg, Germany; 99. Department of Neurology & Stroke, Eberhard-Karls University, Tuebingen, Germany ; 100. Hertie Institute for Clinical Brain Research, Eberhard-Karls University, Tuebingen, Germany; 101. Department of Neurology, Klinikum Ludwigshafen, Ludwigshafen/ Rhein, Germany; 102. Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany; 103. Department of Neurology and Experimental Neurology, Center for Stroke Research Berlin, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Germany; 104. Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie, Hamburg, Germany; 105. Second Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Faculty of Health Sciences, Greece; 106. Stroke Unit, Metropolitan Hospital, Piraeus, Greece; 107. Hospital General San Juan de Dios, Guatemala; 108.

Mazumdar Shaw Medical Center, Bangalore, Karnataka, India; 109. Department of Neurology, Apollo Specialty Hospitals Nellore, Andhra Pradesh, India; 110. Department of Neurology, Grant Medical College and Sir JJ Hospital, Mumbai, India; 111. Mazumdar Shaw Medical Center, Bangalore, Karnataka, India 112. Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India; 113. Department of Neurology, Faculty of Medicine Udayana University, Sanglah General Hospital Denpasar, Bali, Indonesia; 114. Dr. Soetomo General Hospital Surabaya, Universitas Airlangga, Indonesia; 115. Stroke Research Group, Head of Stroke Care Unit, Department of Neurology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Iran; 116. Neurosciences Research Center, Imam Reza Hospital, Tabriz University of Medical Sciences,Tabriz, Iran; 117. Neurology Department, Hillel Yaffe Medical Center, Hadera, Israel; 118. Neurointerventional Unit, Shamir Medical Center, Israel; 119. Stroke Unit, University of Siena, Siena, Italy; 120. Stroke Center IRCCS Sacro Cuore Don Calabria, Verona, Italy; 121. Dipartimento di Neuroradiologia Diagnostica e Interventistica Policinico Universitario IRCCS San Martino, Genova, Italy; 122. Neurology and Stroke Unit, Ospedale Bufalini, Cesena, Italy; 123. Neuroscience Section, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; 124. Interventional Neurovascular Unit, Careggi University Hospital, Florence, Italy; 125. Neurological Department, "Alessandro Manzoni" Hospital, ASST Lecco, Via dell'Eremo, Lecco, Italy; 126. IRCCS Istituto delle Scienze Neurologiche di Bologna, Neurologia e Rete Stroke Metropolitana, Bologna, Italy; 127. Department of Neurosurgery, Iwate Prefectural Central Hospital, Japan; 128. Department of Neurology, Japanese Red Cross Matsue Hospital, Japan; 129. Department of Neurosurgery, National Hospital Organization Osaka National Hospital, Japan; 130. Department of Endovascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan; 131. Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan; 132. NTT Medical Center Tokyo, Tokyo, Japan; 133. Department of Neurosurgery, Iwate Prefectural Central Hospital, Japan; 134. Department of Neurology, Kin-ikyo Chuo Hospital, Japan; 135. Shiroyama Hospital, Japan; 136. Department of Neurology, Osaka General Medical Center, Japan; 137. Department of Neurology, The Jikei University School of Medicine, Japan; 138. Department of Neurology, Saiseikai Fukuoka General Hospital, SFGH, Japan; 139. Stroke Center, Osaka University Hospital, Japan; 140. Department of Neurology, Kagoshima City Hospital, Kagoshima, Japan; 141. Department of Neurology, Japanese Red Cross Kyoto Daini Hospital, Japan; 142. Department of Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital, Japan; 143. Comprehensive Strokology, Fujita Health University School of Medicine, Toyoake, Japan; 144. Department of Neurology, Kobe City Medical Center General Hospital, Japan; 145. Department of Neurology, Japanese Red Cross Kummoto Hospital, Japan; 146. Osaka Red Cross Hospital, Japan; 147. Department of Neurology, National Cerebral and Cardiovascular Center, Japan; 148. Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Japan; 149. Cerebrovascular Medicine, Stroke Center, Saga Medical Centre Koseikan, Japan; 150. Stroke Medicine, Kawasaki Medical School, Japan; 151. Department of Neurology and Stroke treatment, Japanese Red Cross Kyoto Daiichi Hospital, Japan; 152. Advanced Brain Research, Tokushima University, Japan; 153. Yokohama Brain and Spine Center, Japan; 154. Department of Stroke Neurology, Kohnan Hospital, Sendai, Japan; 155. Toyonaka Municipal Hospital, Japan; 156. Kenyatta University Teaching, Referral and Research Hospital, Kenya; 157. Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; 158. Department of Neurology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, South Korea; 159. Department of Neurology, National Health Insurance Service Ilsan Hospital, Goyang, Korea; 160. Department of Neurology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea; 161. Department of Urgent Neurology, University Clinic of Neurology, University Ss. Cyril and Methodius-Faculty of Medicine, Skopje, North Macedonia; 162. Hospital Sultan Abdul Halim, Malaysia; 163. Department of Medicine, National University of Malaysia, Malaysia; 164. Department of Surgery, National University of Malaysia, Malaysia; 165. Neurovascular Unit and Neurology Department, University Hospital Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Mexico; 166. Department of Neurology, Hospital de especialidades del Centro Médico Nacional Siglo XXI IMSS, Mexico; 167. Neurovascular Unit and

Neurology Department, University Hospital Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Mexico; 168. “Nicolae Testemitanu” State University of Medicine and Pharmacy; Emergency Medicine Institute, Chisinau, Republic of Moldova, Moldova; 169. Amsterdam University Medical Centers Amsterdam, the Netherlands; 170. Erasmus MC, University Medical Center Rotterdam, Department of Neurology, the Netherlands; 171. Department of Medicine, University of Otago - Wellington, and Department of Neurology, Wellington Hospital, Wellington, New Zealand; 172. Department of Neurology, Christchurch Hospital, Christchurch, New Zealand; 173. Department of Medical Records, Federal Medical Centre, Owo, Ondo State, Nigeria; 174. Neurology Unit, University of Ilorin, Nigeria; 175. Neurology Unit, Department of Medicine, Federal Medical Centre Owerri, Neurology Unit, Federal Medical Centre, Owerri, Nigeria; 176. Department of Medicine, Federal Medical Centre Owerri, Neurology Unit, Federal Medical Centre, Owerri, Nigeria Imo, Nigeria; 177. Neurology Unit, University of Ilorin, Nigeria; 178. Department of Neurology, Akershus University Hospital, Norway, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 179. Department of Neurology, Oslo, Oslo, Norway and The Norwegian Air Ambulance Foundation, Oslo, Norway; 180. Central Stroke Unit, Neuroscience Directorate, Khoula Hospital, Ministry of Health, Oman; 181. Lahore General Hospital, Lahore, Pakistan; 182. Departamento de Neurología, Hospital Nacional Edgardo Rebagliati Martins,Essalud, Lima, Perú; 183. St. Luke's Medical Center, Global City, Philippines; 184. St. Luke's Medical Center, Quezon City, Philippines; 185. Department of Neurology, Specialist Hospital Konskie, Collegium Medicum, Jan Kochanowski University, Kielce, Poland; 186. Clinic of Neurology, Military Institute of Medicine, Warsaw, Poland; 187. Department of Neurology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland; 188. Department of Neurology, St. Jadwiga Provincial Specialist Hospital in Opole, Institute of Medical Sciences, University of Opole, Opole, Poland; 189. Department of Neurology, Leszek Giec Upper Silesian Medical Centre of the Silesian Medical University in Katowice, School of Health Sciences, Medical University of Silesia in Katowice, Katowice, Poland; 190. 1st Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland; 191. Clinic of Neurology, Military Institute of Medicine, Warsaw, Poland; 192. Department of Neurology in Sandomierz, Collegium Medicum, Jan Kochanowski University in Kielce, Sandomierz, Poland; 193. Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland; 194. Department of Neurology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland; Department of Neurology, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland; 195. Neuroradiology Department - Centro Hospitalar de Vila Nova de Gaia/Espinho, Portugal; 196. Neurology Department, Centro Hospitalar Vila Nova de Gaia/Espinho; 197. Department of Neurology, Centro Hospitalar Universitário de São João, Portugal; 198. Stroke Unit - Hospital Pedro Hispano, Matosinhos, Portugal; 199. Stroke Unit, Centro Hospitalar Universitário de Lisboa Central, Portugal; 200. Stroke Unit, Medicine Department, Centro Hospitalar Universitário de São João, Portugal; 201. Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; 202. Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Portugal; 203. Department of Neurology, Hospital Garcia de Orta, Almada, Portugal; 204. Centro Hospitalar Universitário de São João, Portugal; 205. Bucarest University Emergency Hospital, Romania; 206. Department of Neurology, County Clinic Hospital, Faculty of Medicine, Transilvania University, Brasov, Romania; 207. Department of Neurology King Fahad Hospital of the University Imam Abdulrahman bin Faisal University Dammam, Saudi Arabia; 208. Raffles Hospital, Singapore; 209. Department of Neurology, Faculty Hospital Trnava, Slovakia; Jessenius Medical Faculty, Martin, Commenius University, Bratislava, Slovakia; 210. Department of Neurology, Slovak Medical University, Bratislava, Slovakia; 211. Complejo Hospitalario Universitario de Albacete, Albacete, Spain; 212. Interventional Neuroradiology, Hospital Clínic de Barcelona, Spain; 213. Comprehensive Stroke Center, Hospital Clínic de Barcelona, Spain; 214. Department of Neurology (Unidad de Ictus), Hospital Universitario Ramón y Cajal, Madrid, Spain; 215. Stroke Unit, Neurology Department, Hospital Universitario Virgen del Rocío, Spain; 216. Department of Neurology, Hospital Universitario Virgen Macarena & Neurovascular Research Laboratory, Instituto de Biomedicina de Sevilla-IbiS, Spain; 217. Department of Neuroradiology, Hospital Universitario Rey Juan Carlos, Spain; 218. Department of

Neurology, Hospital Universitario Rey Juan Carlos, Spain; 219. Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg; 220. Department of Neurology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; 221. Department of Neurology, Karolinska University Hospital & Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden; 222. Interventional Neuroradiology, University Hospitals of Geneva, Switzerland; 223. Department of Neurology, Inselspital, Bern University Hospital; 224. Neurocenter, Cantonal Hospital of Lucerne, Lucerne, Switzerland; 225. Department of Neurology, University Hospitals of Geneva, Switzerland; 226. Diagnostic and Interventional Neuroradiology, Bern University Hospital, University of Bern, Switzerland; 227. Radiology and Nuclear Medicine, Cantonal Hospital of Lucerne, Luzerne, Switzerland; 228. University Hospital, University of Zurich, Switzerland; 229. Department of Neurology, Tainan Sin Lau Hospital, Tainan City, Taiwan; 230. Ramathibodi Hospital, Mahidol University, Thailand; 231. Department of Radiology, Siriraj Hospital, Mahidol University, Thailand; 232. Eskisehir Osmangazi University, Turkey; 233. Istanbul Aydın University, Florya Medicalpark Stroke Center, Turkey; 234. Cleveland Clinic Abu Dhabi, UAE; 235. Department of Stroke Medicine, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK; 236. Stroke, Department of Medicine, Nottingham University Hospitals NHS Trust, UK; 237. Neuroradiology, Nottingham University Hospitals NHS Trust, UK; 238. Barking Havering and Redbridge University Hospitals, Romford, UK; 239. Royal London Hospital, Barts Health NHS Trust, London, UK; 240. St George's University Hospital, London, UK; 241. Valley Hospital Health System, Neurosurgeons of NJ, New Jersey, USA; 242. Amita Health and University of Illinois-Chicago, Chicago, USA; 243. Inova Fairfax Hospital, Virginia, USA; 244. Neuroscience and Stroke Program, Bon Secours Mercy Health St Vincent Hospital, Toledo, Ohio; 245. Loyola University Chicago Stritch School of Medicine, Illinois, USA; 246. Inova Fairfax Hospital, University of Virginia School of Medicine, Virginia, USA; 247. Rush University Medical Center, Chicago, Illinois, USA; 248. Department of Neurology, Henry Ford Health System, Detroit, Michigan, USA; 249. Clinical Data Specialist, EBC Data Abstraction, University of Tennessee Health Science Center, Tennessee, USA; 250. Solution Architect II, Clinical Decision Support, University of Tennessee Health Science Center, Tennessee, USA; 251. Department of Radiology, University of Texas Medical Branch, Galveston, Texas, USA; 252. Neurology, UTHealth McGovern Medical School, Houston, Texas, USA; 253. Department of Neurology, Yale University School of Medicine, New Haven, USA; 254. Brigham and Women's Hospital, Boston, USA; 255. Baptist Health Medical Center - Little Rock, Little Rock, Arkansas, USA; 256. Neurointerventional Program, Departments of Medical Imaging & Clinical Neurological Sciences, London Health Sciences Centre, Western University, London ON; Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women’s Hospital, Harvard Medical School, Boston MA; 257. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA; 258. Department of Interventional and Vascular Neurology, Neuroscience Center, SSM Health DePaul Hospital, St. Louis, Missouri, USA; 259. University of Iowa, Iowa, USA; 260. Santa Barbara Cottage Hospital, California, USA; 261. Department of Neurology, Saint Louis University School of Medicine, Missouri, USA; 262. Department of Neurology, Wake Forest Baptist Medical Center, NC, USA; 263. Wayne State University, Detroit, MI, Detroit, Michigan, USA; 264. Department of Neurosciences and Comprehensive Stroke Center, Spectrum Health and Michigan State University College of Human Medicine, Michigan, USA; 265. Department of Neurology, Grady Memorial Hospital, Emory University School of Medicine, USA; 266. Department of Neurosurgery, University of Texas Medical Branch, USA; 267. Department of Neurology, Texas Tech University Health Science Center, El Paso, Texas; 268. HSHS St. John's Hospital, Southern Illinois University School of Medicine, Springfield, USA; 269. Virginia Hospital Center, Virginia, USA; 270. Baptist Health Medical Group, Baptist Health Lexington, Lexington, Kentucky, USA; 271. Division of Neurointerventional Radiology, Department of Radiology, University of Massachusetts Medical Center, Worcester, Massachusetts, USA; 272. Community Memorial Hospital, Ventura, California, USA; 273. Vascular and Neurointerventional Services, Saint Louis University, Missouri, USA; 274. Miami Cardiac & Vascular Institute, Miami Neuroscience Institute, Miami, FL, USA; 275. Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA; 276. Department of Neurology, Wake Forest Baptist

Medical Center, NC, USA; 277. Department of Neurology & Neurosurgery, ECU Health Medical Center, Greenville, North Carolina, USA; 278. Department of Neurology, University of Kansas Medical Center, USA; 279. West Virginia University, USA; 280. Department of Neurology, SUNY Upstate, Syracuse, New York, USA; 281. Department of Neurology, Medical University of South Carolina, USA; 282. Department of Neurosurgery, University at Buffalo, USA; 283. Department of Neurology, Pediatrics, Emory University, Georgia, USA; 284. Department of Neurology, University of Arkansas for Medical Sciences, Arkansas, USA; 285. Ascension St Johns Medical Center, Tulsa, Oklahoma, USA; 286. Riverside Regional Medical Center, Newport News, Virginia, USA; 287. Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, USA; 288. University of Colorado School of Medicine, Aurora, Colorado, USA; 289. Miami Neuroscience Institute, Miami, USA; 290. UNC School of Medicine, North Carolina, USA; 291. University of Utah, Utah, USA; 292. Hue Central, Hue, Vietnam; 293. Da Nang Hospital, Da Nang, Vietnam; 294. Bach Mai Hospital, Hanoi, Vietnam; 295. Department of Neurology, Basel University Hospital, University of Basel, Switzerland; 296. Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 297. Department of Neurology, Federal University of Rio Grande do Sul, Porto Alegre; Hospital de Clínicas de Porto Alegre, Brazil; 298. Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, USA.

Equal Author Contribution:

Contributions:
Thanh N. Nguyen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Muhammad M Qureshi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: Dr. performed the statistical analysis for the study.
Piers Klein: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Hiroshi Yamagami: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Robert Mikulik: Major role in the acquisition of data
Anna Czlonkowska: Major role in the acquisition of data
Mohamad Abdalkader: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Petra Sedova: Major role in the acquisition of data
Anvitha Sathya: Major role in the acquisition of data
Hannah C. Lo: Major role in the acquisition of data
Ossama Yassin Mansour: Major role in the acquisition of data
Husitha Reddy Vanguru: Major role in the acquisition of data
Emilie Lesaine: Major role in the acquisition of data
Georgios Tsivgoulis: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Aaron I. Loochtan: Major role in the acquisition of data
Jelle Demeestere: Major role in the acquisition of data
Ken Uchino: Major role in the acquisition of data
Violiza Inoa: Major role in the acquisition of data
Nitin Goyal: Major role in the acquisition of data
Andreas Charidimou: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

James E. Siegler: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Shadi Yaghi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Diana Aguiar de Sousa: Major role in the acquisition of data
Mahmoud Mohammaden: Major role in the acquisition of data
Diogo C Haussen: Major role in the acquisition of data
Espen Saxhaug Kristoffersen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Virginia Pujol Lereis: Major role in the acquisition of data
Sergio Daniel Scollo: Major role in the acquisition of data
Bruce C. V. Campbell: Major role in the acquisition of data; Study concept or design
Alice Ma: Major role in the acquisition of data
James Orton Thomas: Major role in the acquisition of data
Mark W Parsons: Major role in the acquisition of data
Shaloo Singhal: Major role in the acquisition of data
Lee-Anne Slater: Major role in the acquisition of data
Rodrigo Tomazini Martins: Major role in the acquisition of data
Chris Enzinger: Major role in the acquisition of data
Thomas Gattringer: Major role in the acquisition of data
Aminur Rahman: Major role in the acquisition of data
Thomas Bonnet: Major role in the acquisition of data
Noemie Ligot: Major role in the acquisition of data
Sylvie De Raedt: Major role in the acquisition of data
Robin Lemmens: Major role in the acquisition of data
Peter Vanacker: Major role in the acquisition of data
Fenne Vandervorst: Major role in the acquisition of data
Adriana Bastos Conforto: Major role in the acquisition of data
Raquel C.T. Hidalgo: Major role in the acquisition of data
Luciana de Oliveira Neves: Major role in the acquisition of data
Rodrigo Targa Martins: Major role in the acquisition of data
Daissy Liliana Mora Cuervo: Major role in the acquisition of data
Leticia C. Rebello: Major role in the acquisition of data
Igor Bessa Santiago: Major role in the acquisition of data
Isabelle Lameirinhas da Silva: Major role in the acquisition of data
Teodora Sakelarova: Major role in the acquisition of data
Rosen Kalpachki: Major role in the acquisition of data
Filip Alexiev: Major role in the acquisition of data
Luciana Catanese: Major role in the acquisition of data
Elena Adela Cora: Major role in the acquisition of data
Mayank Goyal: Major role in the acquisition of data
Michael D. Hill: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Michael E. Kelly: Major role in the acquisition of data
Houman Khosravani: Major role in the acquisition of data
Pascale Lavoie: Major role in the acquisition of data
Lissa Peeling: Major role in the acquisition of data
Aleksandra Pikula: Major role in the acquisition of data
Rodrigo Rivera: Major role in the acquisition of data
Hui-Sheng Chen: Major role in the acquisition of data
Yimin Chen: Major role in the acquisition of data

Xiaochuan Huo: Major role in the acquisition of data
Zhongrong Miao: Major role in the acquisition of data
Shuiquan Yang: Major role in the acquisition of data
Marina Roje Bedekovic: Major role in the acquisition of data
Marina Bralic: Major role in the acquisition of data
Hrvoje Budincevic: Major role in the acquisition of data
Angel Basilio Corredor-Quintero: Major role in the acquisition of data
Osvaldo E. Lara-Sarabia: Major role in the acquisition of data
Martin Cabal: Major role in the acquisition of data
Dusan Tenora: Major role in the acquisition of data
Petr Fibrich: Major role in the acquisition of data
Roman Herzig: Major role in the acquisition of data
Helena Hlaváčová: Major role in the acquisition of data
Emanuela Hrabanovska: Major role in the acquisition of data
David Hlinovsky: Major role in the acquisition of data
Lubomir Jurak: Major role in the acquisition of data
Jana Kadlcikova: Major role in the acquisition of data
Igor Karpowicz: Major role in the acquisition of data
Lukas Klecka: Major role in the acquisition of data
Martin Kovar: Major role in the acquisition of data
David Lauer: Major role in the acquisition of data
Jiri Neumann: Major role in the acquisition of data
Hana Palouskova: Major role in the acquisition of data
Martin Reiser: Major role in the acquisition of data
Petra Rekova: Major role in the acquisition of data
Vladimir Rohan: Major role in the acquisition of data
Ondrej Skoda: Major role in the acquisition of data
Miroslav Škorňa: Major role in the acquisition of data
Lenka Sobotková: Major role in the acquisition of data
Martin Sramek: Major role in the acquisition of data
Lenka Zakova: Major role in the acquisition of data
Hanne Christensen: Major role in the acquisition of data
Nicolas Drenck: Major role in the acquisition of data
Helle Klingenberg Iversen: Major role in the acquisition of data
Thomas Clement Truelsen: Major role in the acquisition of data
Troels Wienecke: Major role in the acquisition of data
Khalid Sobh: Major role in the acquisition of data
Pauli Ylikotila: Major role in the acquisition of data
Kemal Alpay: Major role in the acquisition of data
Daniel Strbian: Major role in the acquisition of data
Patricia Bernady: Major role in the acquisition of data
Philippe Casenave: Major role in the acquisition of data
Maria Dan: Major role in the acquisition of data
Jean-Marc Faucheux: Major role in the acquisition of data
Jean-Christophe Gentric: Major role in the acquisition of data
Elsa Magro: Major role in the acquisition of data
Candice Sabben: Major role in the acquisition of data
Peggy Reiner: Major role in the acquisition of data
Francois Rouanet: Major role in the acquisition of data
Ferdinand O. Bohmann: Major role in the acquisition of data
Stefan Boskamp: Major role in the acquisition of data

Joshua Mbroh: Major role in the acquisition of data
Simon Nagel: Major role in the acquisition of data
Christian Nolte: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Peter A. Ringleb: Major role in the acquisition of data
Michael Rosenkranz: Major role in the acquisition of data
Sven Poli: Major role in the acquisition of data
Götz Thomalla: Major role in the acquisition of data
Theodoros Karapanayiotides: Major role in the acquisition of data
Ioanna Koutroulou: Major role in the acquisition of data
Odysseas Kargiotis: Major role in the acquisition of data
Lina Palaiodimou: Major role in the acquisition of data
Jose Dominguo Barrientos Guerra: Major role in the acquisition of data
Vikram Huded: Major role in the acquisition of data
Bindu Menon: Major role in the acquisition of data
Shashank Nagendra: Major role in the acquisition of data
Chintan Prajapati: Major role in the acquisition of data
P.N. Sylaja: Major role in the acquisition of data
Nyoman Angga Krishna Pramana: Major role in the acquisition of data
Achmad Firdaus Sani: Major role in the acquisition of data
Abdoreza Ghoreishi: Major role in the acquisition of data
Mehdi Farhoudi: Major role in the acquisition of data
Elyar Sadeghi Hokmabadi: Major role in the acquisition of data
Tariq Abu Raya: Major role in the acquisition of data
Shani Avnery Kalmanovich: Major role in the acquisition of data
Levite Ronen: Major role in the acquisition of data
Sergiu Ionut Sabetay: Major role in the acquisition of data
Maurizio Acampa: Major role in the acquisition of data
Alessandro Adami: Major role in the acquisition of data
Lucio Castellan: Major role in the acquisition of data
Marco Longoni: Major role in the acquisition of data
Raffaele Ornello: Major role in the acquisition of data
Leonardo Renieri: Major role in the acquisition of data
Claudia Rolla Bigliani: Major role in the acquisition of data
Michele Romoli: Major role in the acquisition of data
Simona Sacco: Major role in the acquisition of data
Andrea Salmaggi: Major role in the acquisition of data
Davide Sangalli: Major role in the acquisition of data
Andrea Zini: Major role in the acquisition of data
Ryosuke Doijiri: Major role in the acquisition of data
Hiroki Fukuda: Major role in the acquisition of data
Toshiyuki Fujinaka: Major role in the acquisition of data
Kyohei Fujita: Major role in the acquisition of data
Hirotoshi Imamura: Major role in the acquisition of data
Nobuyuki Sakai: Major role in the acquisition of data
Takuya Kanamaru: Major role in the acquisition of data
Naoto Kimura: Major role in the acquisition of data
Ryuhei Kono: Major role in the acquisition of data
Kosuke Miyake: Major role in the acquisition of data
Manabu Sakaguchi: Major role in the acquisition of data
Kenichiro Sakai: Major role in the acquisition of data

Kazutaka Sonoda: Major role in the acquisition of data
Kenichi Todo: Major role in the acquisition of data
Fumio Miyashita: Major role in the acquisition of data
Naoki Tokuda: Major role in the acquisition of data
Yuji Matsumaru: Major role in the acquisition of data
Shoji Matsumoto: Major role in the acquisition of data
Nobuyuki Ohara: Major role in the acquisition of data
Seigo Shindo: Major role in the acquisition of data
Yohei Takenobu: Major role in the acquisition of data
Takeshi Yoshimoto: Major role in the acquisition of data
Kazunori Toyoda: Major role in the acquisition of data
Takeshi Uwatoko: Major role in the acquisition of data
Yoshiki Yagita: Major role in the acquisition of data
Takehiro Yamada: Major role in the acquisition of data
Nobuaki Yamamoto: Major role in the acquisition of data
Ryoo Yamamoto: Major role in the acquisition of data
Yukako Yazawa: Major role in the acquisition of data
Yuri Sugiura: Major role in the acquisition of data
Peter Kuria Waweru: Major role in the acquisition of data
Jang-Hyun Baek: Major role in the acquisition of data
Si Baek Lee: Major role in the acquisition of data
Kwon-Duk Seo: Major role in the acquisition of data
Sung-Il Sohn: Major role in the acquisition of data
Anita Ante Arsovska: Major role in the acquisition of data
Yong Chieh Chan: Major role in the acquisition of data
Wan Asyraf Wan Zaidi: Major role in the acquisition of data
Ainul Syahrilfazli Jaafar: Major role in the acquisition of data
Fernando Gongora-Rivera: Major role in the acquisition of data
Manuel Martinez-Marino: Major role in the acquisition of data
Adrian Infante-Valenzuela: Major role in the acquisition of data
Stanislav Groppa: Major role in the acquisition of data
Pavel Leahu: Major role in the acquisition of data
Jonathan M. Coutinho: Major role in the acquisition of data
Leon A. Rinkel: Major role in the acquisition of data
Diederik W.J. Dippel: Major role in the acquisition of data
Dianne H.K. van Dam-Nolen: Major role in the acquisition of data
Annemarei Ranta: Major role in the acquisition of data
Teddy Y Wu: Major role in the acquisition of data
Tajudeen Temitayo Adebayo: Major role in the acquisition of data
Abiodun H. Bello: Major role in the acquisition of data
Ernest Okwundu Nwazor: Major role in the acquisition of data
Taofiki Ajao Sunmonu: Major role in the acquisition of data
Kolawole Wasiu Wahab: Major role in the acquisition of data
Ole Morten Ronning: Major role in the acquisition of data
Else Charlotte Sandset: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Amal M. Al Hashimi: Major role in the acquisition of data
Saima Ahmad: Major role in the acquisition of data
Umair Rashid: Major role in the acquisition of data
Liliana Rodriguez-Kadota: Major role in the acquisition of data
Miguel Ángel Vences: Major role in the acquisition of data

Patrick Matic Yalung: Major role in the acquisition of data
Jon Stewart Hao Dy: Major role in the acquisition of data
Maria Carissa Pineda-Franks: Major role in the acquisition of data
Christian Oliver Co: Major role in the acquisition of data
Waldemar Brola: Major role in the acquisition of data
Aleksander Debiec: Major role in the acquisition of data
Malgorzata Dorobek: Major role in the acquisition of data
Michal Adam Karlinski: Major role in the acquisition of data
Beata M. Labuz-Roszak: Major role in the acquisition of data
Anetta Lasek-Bal: Major role in the acquisition of data
Halina Sienkiewicz-Jarosz: Major role in the acquisition of data
Jacek Staszewski: Major role in the acquisition of data
Piotr Sobolewski: Major role in the acquisition of data
Marcin Wiacek: Major role in the acquisition of data
Justyna Zielinska-Turek: Major role in the acquisition of data
Andre Pinho Araujo: Major role in the acquisition of data
Mariana Rocha: Major role in the acquisition of data
Pedro Castro: Major role in the acquisition of data
Vitor Tedim Cruz: Major role in the acquisition of data
Paulo Venancio Ferreira: Major role in the acquisition of data
Patricia Ferreira: Major role in the acquisition of data
Ana Paiva Nunes: Major role in the acquisition of data
Luisa Fonseca: Major role in the acquisition of data
João Pedro Marto: Major role in the acquisition of data
Teresa Pinho e Melo: Major role in the acquisition of data
Miguel Rodrigues: Major role in the acquisition of data
M Luis Silva: Major role in the acquisition of data
Adela Dimitriade: Major role in the acquisition of data
Cristian Falup-Pecurariu: Major role in the acquisition of data
May Adel Hamid: Major role in the acquisition of data
Narayanaswamy Venketasubramanian: Major role in the acquisition of data
Georgi Krastev: Major role in the acquisition of data
Miroslav Mako: Major role in the acquisition of data
Oscar Ayo-Martin: Major role in the acquisition of data
Francisco Hernández-Fernández: Major role in the acquisition of data
Jordi Blasco: Major role in the acquisition of data
Alejandro Rodríguez-Vázquez: Major role in the acquisition of data
Antonio Cruz-Culebras: Major role in the acquisition of data
Francisco Moniche: Major role in the acquisition of data
Joan Montaner: Major role in the acquisition of data
Soledad Perez-Sanchez: Major role in the acquisition of data
María Jesús García Sánchez: Major role in the acquisition of data
Marta Guillán Rodríguez: Major role in the acquisition of data
Katarina Jood: Major role in the acquisition of data
Annika Nordanstig: Major role in the acquisition of data
Michael V. Mazya: Major role in the acquisition of data
Tiago T.P. Moreira: Major role in the acquisition of data
Gianmarco Bernava: Major role in the acquisition of data
Morin Beyeler: Major role in the acquisition of data
Manuel Bolognese: Major role in the acquisition of data
Emmanuel Carrera: Major role in the acquisition of data

Tomas Dobrocky: Major role in the acquisition of data
Grzegorz Marek Karwacki: Major role in the acquisition of data
Emanuela Keller: Major role in the acquisition of data
Chang Yang Hsieh: Major role in the acquisition of data
Surawan Boonyakarnkul: Major role in the acquisition of data
Anchalee Churojana: Major role in the acquisition of data
Ozlem Aykac: Major role in the acquisition of data
Atilla Özcan Ozdemir: Major role in the acquisition of data
Arsida Bajrami: Major role in the acquisition of data
Songul Senadim: Major role in the acquisition of data
Syed Irteza Hussain: Major role in the acquisition of data
Seby John: Major role in the acquisition of data
Soma Banerjee: Major role in the acquisition of data
Joseph Kwan: Major role in the acquisition of data
Kailash Krishnan: Major role in the acquisition of data
Robert Lenthall: Major role in the acquisition of data
Ashok Matthews: Major role in the acquisition of data
Ken Wong: Major role in the acquisition of data
Liqun Zhang: Major role in the acquisition of data
Dorothea Altschul: Major role in the acquisition of data
Kaiz S. Asif: Major role in the acquisition of data
Zeelalem Bahiru: Major role in the acquisition of data
Kristine Below: Major role in the acquisition of data
José Biller: Major role in the acquisition of data
Sean Ruland: Major role in the acquisition of data
Saqib A. Chaudry: Major role in the acquisition of data
Michael Chen: Major role in the acquisition of data
Alex Chebl: Major role in the acquisition of data
Jackie Cibulka: Major role in the acquisition of data
Leon Cistrunk: Major role in the acquisition of data
Judith Clark: Major role in the acquisition of data
Marco Colasurdo: Major role in the acquisition of data
Alexandra Czap: Major role in the acquisition of data
Adam de Havenon: Major role in the acquisition of data
Salvatore D'Amato: Major role in the acquisition of data
Sushrut Dharmadhikari: Major role in the acquisition of data
Kasey B. Grimmett: Major role in the acquisition of data
Adam A Dmytriw: Major role in the acquisition of data
Mark R Etherton: Major role in the acquisition of data
Chizoba Ezepue: Major role in the acquisition of data
Mudassir Farooqui: Major role in the acquisition of data
Steven K. Feske: Major role in the acquisition of data
Lauren Fink: Major role in the acquisition of data
Ulviyya Gasimova: Major role in the acquisition of data
Amy K. Guzik: Major role in the acquisition of data
Maryam Hakemi: Major role in the acquisition of data
Majesta Hovingh: Major role in the acquisition of data
Muhib Khan: Major role in the acquisition of data
Dinesh Jillela: Major role in the acquisition of data
Peter T. Kan: Major role in the acquisition of data
Rakesh Khatri: Major role in the acquisition of data

Ayaz M. Khawaja: Major role in the acquisition of data
Naim N. Khoury: Major role in the acquisition of data
Nicole L. Kiley: Major role in the acquisition of data
Benny S. Kim: Major role in the acquisition of data
Murali K. Kolikonda: Major role in the acquisition of data
Anna Luisa Kuhn: Major role in the acquisition of data
Stephanie Lara: Major role in the acquisition of data
Guillermo Linares: Major role in the acquisition of data
Italo Linfante: Major role in the acquisition of data
Timothy G. Lukovits: Major role in the acquisition of data
Sarah Lycan: Major role in the acquisition of data
Shailesh S. Male: Major role in the acquisition of data
Laith Maali: Major role in the acquisition of data
John Mancin: Major role in the acquisition of data
Hesham Masoud: Major role in the acquisition of data
Ghada A. Mohamed: Major role in the acquisition of data
Andre Monteiro: Major role in the acquisition of data
Fadi Nahab: Major role in the acquisition of data
Krishna Nalleballe: Major role in the acquisition of data
Santiago Ortega Gutierrez: Major role in the acquisition of data
Ajit S. Puri: Major role in the acquisition of data
Yazan Radaideh: Major role in the acquisition of data
Rahul H. Rahangdale: Major role in the acquisition of data
Ansaar Rai: Major role in the acquisition of data
Pankajavalli Ramakrishnan: Major role in the acquisition of data
Aravind B. Reddy: Major role in the acquisition of data
Diana M. Rojas-Soto: Major role in the acquisition of data
Jose Rafael Romero: Major role in the acquisition of data
Natalia S Rost: Major role in the acquisition of data
Aaron Rothstein: Major role in the acquisition of data
Setareh Salehi Omran: Major role in the acquisition of data
Sunil A. Sheth: Major role in the acquisition of data
Adnan H. Siddiqui: Major role in the acquisition of data
Amy K. Starosciak: Major role in the acquisition of data
Nicholas E. Tarlov: Major role in the acquisition of data
Robert A. Taylor: Major role in the acquisition of data
Michael J. Wang: Major role in the acquisition of data
Jared Wolfe: Major role in the acquisition of data
Ka-Ho Wong: Major role in the acquisition of data
Huynh Vu Le: Major role in the acquisition of data
Quy Viet Nguyen: Major role in the acquisition of data
Thong Nhu Pham: Major role in the acquisition of data
Trung Thanh Nguyen: Major role in the acquisition of data
Hoang Thi Phan: Major role in the acquisition of data
Mai Duy Ton: Major role in the acquisition of data
Urs Fischer: Major role in the acquisition of data
Patrik Michel: Major role in the acquisition of data
Davide Strambo: Major role in the acquisition of data
Sheila O. Martins: Major role in the acquisition of data
Osama O. Zaidat: Major role in the acquisition of data

Raul G Nogueira: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Figure Count:
1

Table Count:
6

Search Terms:
[2] All Cerebrovascular disease/Stroke, [7] Intracerebral hemorrhage, [54] Cohort studies, [335] All global neurology, [360] COVID-19

Acknowledgment:
The authors acknowledge the following contributors for participating in data collection: Megan Brady, MPH, MSW (Henry Ford); Dawn Scozzari, RHIT (Henry Ford); Elisabeth Dirren, MD (Geneva University Hospitals, Geneva, Switzerland); Claudio Rodríguez Fernández (Hospital Universitario rey Juan carlos); Jorge Escartín López (Hospital Universitario rey Juan carlos); José Carlos Fernández Ferro (Hospital Universitario rey Juan carlos); Beatriz de la Cruz Fernández (Hospital Universitario rey Juan carlos); Niloofar Mohammadzadeh as data entry staff in Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Filipe Bessa, MD (Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Portugal); Nina Jancar, MD (Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Portugal); Neil C. Suryadevara, MD (SUNY Upstate, New York, USA).

Study Funding:
The study was funded by the Society of Vascular and Interventional Neurology pilot grant.

Disclosures:
D. Aguiar de Sousa reported speaker fees from Bayer, travel support from Boehringer Ingelheim, participating in an advisory board for Astrazeneca, and DSMB participation for the SECRET trial, outside the submitted work. K. Alpay reported a research grant from The Radiological Society of Finland. D. Altschul reported consulting fees from Stryker, Microvention, Siemens, and stocks in NTI. J. Blasco reported speaker and CEC fees from Stryker and Medtronic, respectively. H. Budinvevic reported speaker fees from Boehringer Ingelheim, Bayer, Pfizer, Berlin, Chemie Menarini, participation in an advisory board for Boehringer Ingelheim - outside the submitted work. M. Bolognese reported participation in the advisory board (AstraZeneca) and speaker fee (Roche) outside the submitted work. L. Catanese reported research grants from Servier Canada Inc., CIHR and the Canadian Stroke Consortium; adjudication fees for Ischemia Care. J. Coutinho has received grants paid to his institution from Boehringer Ingelheim, Bayer and Medtronic. A. Cruz-Culebras reported travel support from Daiichi-Sankyo and fees for participating in an advisory board for Alexion outside the submitted work C. Falup-Pecurariu reported royalties from Springer Nature Publishing Group and Elsevier, Research Grant from Transilvania University Brasov, Speaker fees and honoraria from International Parkinson and Movement Disorders Society, AbbVie, outside the submitted work. M. Farhoudi reported a research grant (number: 700/1483) from the Research & Technology Deputy, Ministry of Health, Iran. U. Fischer reported research grants from Medtronic (BEYOND SWIFT and SWIFT DIRECT); serving as consultant for Medtronic, Stryker, CSL Behring; and participating in an advisory board for Alexion/Portola outside the submitted work. H. Imamura reported lecturer's fees from Medtronic and Stryker outside the submitted work. H.K. Iversen reported fees as advisory board member or lecturer from Bayer, Bristol Myers Squibb, Pfizer and Boehringer Ingelheim. P.T. Kan reported consulting for Stryker Neurovascular and Imperative Care; stock ownership in InNeuroCo and Deinde. P.T. Kan received grant support from NIH U18EB029353-01 and Medtronic. E. Keller reported reported consulting fees for consultancy for Roche, Zoll Medical, Bard

Medical outside the submitted work I. Linfante reported consulting fees from Penumbra, Medtronic, Stryker, Microvention, InNeuroCo, and Three Rivers. P. Michel reported grants from Swiss National Science Foundation and Swiss Heart Foundation outside the submitted work. R. Mikulik was supported by project No. CA18118, IRENE COST Action funded by COST Association, by the IRIS-TEPUS Project No. LTC20051 from the INTER-EXCELLENCE INTER-COST Program of the Ministry of Education, Youth and Sports of the Czech Republic, and by STROCZECH within CZECRIN Large Research Infrastructure No. LM2018128 funded by the state budget of the Czech Republic. S. Nagel reported personal fees for consultancy for Brainomix and payment for lectures including speaker bureaus with Boehringer Ingelheim and Pfizer outside the submitted work. T.N Nguyen reported research support from Medtronic and SVIN (related). C. Nolte reported consulting fees from Abbot, Alexion, Boehringer-Ingelheim, Bayer Pharma, Bristol-Myers Squibb, Daichii Sankyo and Pfizer Pharma. R.G. Nogueira reported consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse, and Perfuze; and investments in Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, and Viseon. R. Ornello reported personal fees from Novartis, Teva, Eli Lilly, and non-financial support from Allergan/AbbVie, Novartis, and Teva, outside the submitted work. S. Ortega-Gutierrez reports being a consultant for Medtronic and Stryker Neurovascular and receiving grants from Stryker, IschemiaView, Viz.ai, and Siemens. A. Pikula reported research grants from CIHR and the Canadian Stroke Consortium A.S. Puri is a consultant for Cerenovus, CereVasc, Merit and Medtronic; research grant from Medtronic. Stocks in InNeuroCo, Galaxy, Agile, Perfuze, and NTI. A. Ranta reported research funding support from the New Zealand health Research Council and the New Zealand Ministry of Health. P. Ringleb reported personal fees from Boehringer Ingelheim, Bayer, Bristol Myers Squibb, and Pfizer outside the submitted work. N. Sakai reported research grants from Daiichi-Sankyo, Medtronic, Terumo, lecture fees from Asahi Intec, Daiichi-Sankyo, Medtronic, Stryker, outside of the submitted work. P. Sedova and R. Mikulik were supported by the project No. CA18118, IRENE COST Action - Implementation Research Network in Stroke Care Quality, by the project No. LQ1605 from the National Program of Sustainability II, by the IRIS-TEPUS Project No. LTC20051 from the INTER-EXCELLENCE INTER-COST program of the Ministry of Education, Youth and Sports of the Czech Republic. Dr Sheth reported research grants from the National Institutes of Health (grants U18EB029353 and R01NS121154), American Academy of Neurology/the SVIN and consultancy fees from Penumbra and Cerenovus. Dr Siegler reported consulting fees from Ceribell and speakersÂ’ bureau involvement with AstraZeneca outside the submitted work. M. Škorňa reported speaker fees from Pfizer, Medtronic, Boehringer Ingelheim and Bayer. G. Thomalla reported fees as a consultant or lecturer from Acandis, Alexion, Amarin, Bayer, BristolMyersSquibb/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Portola, and Stryker. K. Toyoda received lecture honoraria from Daiichi-Sankyo, Otsuka, Novartis, Abbott, Bayer Yakuhin, and Bristol-Myers Squibb outside the submitted work. W. Asyraf Wan Zaidi reported consultant or lecturere fees from Allm inc, Boehringer Ingelheim,Bayer, EP Plus,Medtronic, Pfizer and Stryker. H. Yamagami reported research grants from Bristol-Myers Squibb, lecturer's fees from Bayer, Daiichi-Sankyo, Stryker, and membership of the advisory boards for Daiichi-Sankyo outside the submitted work. O.O. Zaidat reported consulting fees for Stryker, Medtronic, Cerenovus, and Penumbra; research grants from Stryker, Medtronic, Cerenovus, Penumbra, and Genentech; O.O. Zaidat had a patent for Ischemic Stroke issued. M.A. Khan reported research funding from MSU-Spectrum Alliance, Genentech and National Institute of Health unrelated to this manuscript. The other authors report no relevant disclosures.

Preprint DOI:

Received Date:
2021-12-14

Accepted Date:
2022-09-02

Handling Editor Statement:
Submitted and externally peer reviewed. The handling editor was José Merino, MD, MPhil, FAAN.

ABSTRACT

Background and Objectives: Declines in stroke admission, intravenous thrombolysis, and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the impact of the COVID-19 pandemic on the volumes of stroke admissions, intracranial hemorrhage (ICH), intravenous thrombolysis (IVT), and mechanical thrombectomy over a one-year period at the onset of the pandemic (March 1, 2020, to February 28, 2021) compared with the immediately preceding year (March 1, 2019, to February 29, 2020).

Methods: We conducted a longitudinal retrospective study across 6 continents, 56 countries, and 275 stroke centers. We collected volume data for COVID-19 admissions and 4 stroke metrics: ischemic stroke admissions, ICH admissions, intravenous thrombolysis treatments, and mechanical thrombectomy procedures. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases.

Results: There were 148,895 stroke admissions in the one-year immediately before compared to 138,453 admissions during the one-year pandemic, representing a 7% decline (95% confidence interval [95% CI 7.1, 6.9]; p<0.0001). ICH volumes declined from 29,585 to 28,156 (4.8%, [5.1, 4.6]; p<0.0001) and IVT volume from 24,584 to 23,077 (6.1%, [6.4, 5.8]; p<0.0001). Larger declines were observed at high volume compared to low volume centers (all p<0.0001). There was no significant change in mechanical thrombectomy volumes (0.7%, [0.6,0.9]; p=0.49).

Stroke was diagnosed in 1.3% [1.31,1.38] of 406,792 COVID-19 hospitalizations. SARS-CoV-2 infection was present in 2.9% ([2.82,2.97], 5,656/195,539) of all stroke hospitalizations.

Discussion: There was a global decline and shift to lower volume centers of stroke admission volumes, ICH volumes, and IVT volumes during the 1st year of the COVID-19 pandemic compared to the prior year. Mechanical thrombectomy volumes were preserved. These results suggest preservation in the stroke care of higher severity of disease through the first pandemic year.

Trial Registration Information: This study is registered under NCT04934020.

Keywords: COVID-19, acute stroke, ischemic stroke, intracranial hemorrhage, intravenous thrombolysis, mechanical thrombectomy

Classification of Evidence: not applicable as no intervention was conducted.

BACKGROUND:

More than two years after the COVID-19 pandemic was declared in early 2020, over 500 million confirmed cases and 6 million deaths have been reported worldwide. While pulmonary dysfunction is the most common symptom of COVID-19, infection also yields significant disruption of the coagulation system and is a potential trigger for ischemic stroke.[1–3]

Stroke represents an important complication in an estimated 1.1% to 1.5% of COVID-19 admitted patients.[4–8] As a result of the early surge in COVID-19 admissions, the allocation of healthcare resources and the delivery of stroke care have been impacted.[9–13] During the first wave of the COVID-19 pandemic in 2020, declines in stroke admission volumes, intravenous

thrombolysis (IVT), and mechanical thrombectomy have been reported across regional,[14–17] national[18–23] and global[6,24–29] studies. In our initial report covering the first 4 months of the COVID-19 pandemic, we observed a greater than 10% decrease in global stroke admissions, IVT treatments, and IVT transfers, followed by recovery of stroke volume in later months. This report demonstrated the substantial impact of the first wave of the COVID-19 pandemic on global stroke volumes. In the later part of 2020, a "second wave" of the pandemic caused surges in COVID-19 cases throughout the globe. The effects of changes in governmental responses to this second wave, including increased public education efforts and intermittent lockdowns during the 1st year, are scarce. Here, we report the impact of COVID-19 on global stroke volumes over the 1st year of the pandemic.

Study Objective and Hypothesis

The primary objective of this study was to evaluate the one-year volumes of the following stroke metrics: (1) ischemic stroke admissions, (2) intracranial hemorrhage (ICH) admissions, (3) intravenous thrombolysis, (4) mechanical thrombectomy (MT) during the pandemic (March 1, 2020, to February 28, 2021) and compare these metrics to the same one-year period immediately prior (March 1, 2019, to February 29, 2020).

Our primary prespecified hypotheses were that, in the setting of the pandemic's continued strain on healthcare resources, (1) there would be a reduction in all the aforementioned stroke metrics and (2) centers with more COVID-19 volumes would report greater decreases in stroke admissions.

METHODS:

Study design

This was a cross-sectional, observational, retrospective follow-up study evaluating monthly aggregate volumes of consecutive patients hospitalized with a diagnosis of ischemic stroke, intracranial hemorrhage, or COVID-19, and acute reperfusion therapies including intravenous thrombolysis and mechanical thrombectomy. The diagnosis was identified by stroke databases or related ICD-10 codes (primary, secondary, or tertiary discharge codes).

This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline (**eTable 1**). The study is registered NCT04934020 (clinicaltrials.gov).

Setting and participants

Data were collected from collaborators of a prior global study during the first wave of the pandemic, which consisted of 457 stroke centers across 70 countries.[7] These sites were selected by contact with stroke leaders of national and international stroke societies, who invited sites within their network to participate in this study. These societies included the Society of Vascular and Interventional Neurology, the European Stroke Organization, the Middle East North Africa Stroke and Interventional Neurotherapies Organization, the Japanese Society of Vascular and Interventional Neurology, and the Latin America Stroke Group. An additional 23 sites were invited by publicly available information via institution email addresses.

A comprehensive stroke center was defined as a center that offered mechanical thrombectomy; a primary stroke center (PSC) was defined as a center that did not. Centers with no thrombectomy service at the beginning of the study period that later became thrombectomy capable during the study period were classified as PSC; these centers were excluded from the mechanical thrombectomy analysis. Of the 480 centers invited to contribute to this follow-up one-year study, we received data from 275 stroke centers across 56 countries and 6 continents. Each center was verified for profound drops in volume (i.e. > 50%) that may have biased the analysis. Potential confounders including rerouting or diversion of cases to another hospital were inquired to centers where profound drops in volume were noted. Centers were excluded due to incomplete data during the study period for ischemic stroke (30 centers), intracranial hemorrhage (36 centers), intravenous thrombolysis (36 centers) and mechanical thrombectomy (76 centers).

We defined the beginning of the pandemic in each country based on the date of the first reported case.[30] (**eTable 2**) We defined the second wave with two definitions. Our primary definition was that the number of COVID-19 cases must decline by greater than 50% from the previous wave's peak and more than double at the next peak. The start date for this occurrence was chosen as the minimum closest to the second wave. Secondarily, we defined the second wave as the first definition, with the addition of two or more months apart between the peak of the first wave and the start of the second wave.[31] (**eTable 2**)

Data were collected between May 1, 2021, to September 15, 2021, via electronic medical record to capture completely coded data through the end of the study period, May 31, 2021. Data were submitted to the coordinating sites, Boston Medical Center and Emory University School of

Medicine, via excel sheet. Data verification was conducted with the receipt of data from each site by the lead author (TNN), with additional queries related to incomplete data entry returned to submitting authors, with deadline extension to October 30, 2021. The Principal Investigator (PI, TNN) and the lead statistician had access to all data. Investigators at the coordinating sites had access to site-level data for the purposes of data merging, data verification, and statistical analysis.

Study variables and outcome measures

Study variables were collected as monthly aggregate volumes. Ischemic stroke admission was defined as admission to a hospital with a transient ischemic attach (TIA) or ischemic stroke as the primary diagnosis. IVT was defined as acute ischemic stroke treatment with IVT. ICD-10 codes for ischemic stroke utilized were as follows: I63.0 (Cerebral Infarction), I63.1 (Cerebral infarction due to embolism of precerebral arteries), I63.2 (Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries), I63.3 (Cerebral infarction due to thrombosis of cerebral arteries), I63.4 (Cerebral infarction due to embolism of cerebral arteries), I63.5 (Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries), I63.8 (Other cerebral infarction), I63.9 (Cerebral infarction, unspecified). A physician, stroke or research coordinator verified case ascertainment by existing stroke databases, including the Get with the Guidelines Stroke Database, the Czech Republic National Stroke Database, and the Japan National Stroke Database.

Intracranial hemorrhage was defined as admission to a hospital with an intracranial or intracerebral hemorrhage as the primary diagnosis. ICD-10 codes for ICH utilized were as

follows: I61 (Nontraumatic ICH), I61.0 (Nontraumatic ICH in hemisphere, subcortical), I61.1 (Nontraumatic ICH in hemisphere, cortical), I61.2 (Nontraumatic ICH in hemisphere, unspecified), I61.3 (Non-traumatic ICH in the brain stem), I61.4 (Nontraumatic ICH in the cerebellum), I61.5 (Non-traumatic ICH, intraventricular), I61.6 (Nontraumatic ICH, multiple localized), I61.8 (Other non-traumatic ICH), I61.9 (Nontraumatic ICH, unspecified).

COVID-19 admission was defined as any patient admitted with a COVID-19 diagnosis to the hospital, encompassing a non-neurologic diagnosis. The ICD-10 code for COVID-19 diagnosis utilized was UO7.1.

Bias

Centers were screened for potential duplicate data. To avoid data reporting lag bias, we did not include centers with incomplete data for the variable of interest. Centers submitting data from a stroke network were asked not to duplicate IVT or large vessel occlusion patients transferred from a primary stroke center to a comprehensive stroke center. Primary stroke centers were excluded from the MT analysis. In certain nations, COVID-19 case volumes did not demonstrate distinct peaks, either due to consistently high volumes (e.g. Guatemala) or extremely low volumes (e.g. New Zealand), obscuring pandemic waves.

Statistical analysis

First, we compared percentage change in the absolute number of ischemic stroke, ICH, IVT, and MT admissions before and during the COVID-19 pandemic. The 95% confidence intervals for percentage change were calculated using the Wilson procedure without correction for

continuity.[32] The method is computationally simpler with good coverage properties. The differences in admissions across the two periods were assessed for significance using the Poisson Means test. The analysis was repeated by hospital volume (low, intermediate, or high), stroke center (primary or comprehensive), and hospital COVID-19 volume (low, intermediate, or high). The relative percentage decrease in volume between different categories (for example, low vs. intermediate hospital volume) was tested using the z test of proportion.

We then compared average monthly volumes (admissions/month) of ischemic stroke, ICH, IVT, and MT before and during the COVID-19 pandemic. The data were analyzed in a mixed design using a repeated-measures analysis of variance (PROC MIXED analysis in SAS) for accounting for the paired data structure and potential covariates. The auto-regressive, compound symmetrical, and unstructured variance-covariance matrix structures were analyzed for the best model determined by Akaike's Information Criterion. The unstructured matrix was the best fit and was used for the analyses. The monthly hospital volume analysis was adjusted for the date of the peak COVID-19 volume for each country, the start date of the second wave, and the continent. Estimated marginal means were calculated using the LSMEANS statement in PROC MIXED. Similar to the overall volume analysis, monthly volume analysis was stratified by hospital volume, stroke center, and COVID-19 volume.

Finally, we performed a supplementary analysis comparing percentage change in absolute volume and monthly volume between before and during COVID-19 periods across different continents of the world. All data were analyzed using SAS version 9.4 (SAS Institute), and the significance level was set at a P-value of <.05.

Standard Protocol Approvals, Registrations, and Patient Consents

This was an investigator-initiated study. As this was a continuation of our prior work, the institutional review boards from the coordinating sites (Emory University and Boston Medical Center) considered that the investigators did not have access to protected health information in this follow-up study, and thus no IRB oversight was required since the study did not meet the US federal description of human subject research. Site-specific IRB approval was obtained where required by local regulations or institutional policy. There was no protective health information data included in this study. The study was funded by the Society of Vascular and Interventional Neurology research pilot grant. This study was registered under NCT04934020.

Data Availability

Data are available upon reasonable request to the corresponding author.

RESULTS:

Overall, there were 345,089 ischemic stroke and intracranial hemorrhage admissions across the two epochs one-year pre-pandemic and the first year during the pandemic. There were 24,584, 23,077 IVT therapies (overall IVT, n= 47,661) and 18,375, 18,507 mechanical thrombectomy procedures (overall MT, n=36,882) included across the prior-year pandemic, and 1-year pandemic period, respectively **(Figure, A, B**). Data contributions by continent and their relative changes across the pandemic are presented in **eTables 3-6**.

Ischemic Stroke Admissions

There were 148,895 admissions for ischemic stroke in the 1-year pre-pandemic, and 138,453 admissions during the 1-year pandemic, representing a 7% absolute decrease ([95% CI -7.1,-6.9]; p<0.0001, n=245 sites) in ischemic stroke admissions; monthly mean (SE) volume decreased accordingly (43.8 (4.0) to 40.3 (3.9); p<0.0001, n=251 sites). The observed relative decrease in volumes was larger at higher volume stroke admission centers (low vs. intermediate vs. high; p<0.0001) and higher volume COVID-19 centers (low vs. intermediate vs. high; p<0.0001). In the tertile of high volume stroke centers, 32/71 (45%) of centers were high tertile COVID-19 centers. The observed decrease in volumes was smaller at comprehensive stroke centers than primary stroke centers (-6.8% vs. -8.2%; p<0.0001) (**Table 1**).

Geographic variation was noted in the change of ischemic stroke admissions over the 1-year period: Europe, -5.7% ([-5.9,-5.5]; p<0.0001); North America, -6.2% ([-6.5,-6.0]; p<0.0001); Asia, -10.6% ([-11.0,-10.3]; p<0.0001); South America, -13.3% ([-14.4,-12.2]; p<0.0001); Oceania, 4.7% ([4.0-5.4]; p=0.05); Africa, -15.3% ([-18.6,-12.5]; p=0.008) (**eTable 3**).

Intracranial Hemorrhage Admissions

There were 29,585 admissions for intracranial hemorrhage in the 1-year pre-pandemic, and 28,156 admissions during the 1-year pandemic, representing a 4.8% absolute decrease ([-5.1,-4.6]; p<0.0001, n=239 sites); monthly mean (SE) volume decreased (9.7 (1.1) to 9.2 (1.1); p=0.015, n=246 sites). The observed decrease in volumes was greater at high volume compared to intermediate volume (p<0.0001) centers and with a gradient of decrease in higher volume COVID-19 centers (low vs intermediate vs high; p<0.0001). At low volume ICH centers, there

was a 14.6% ([13.2,16.1]; p<0.0001) increase in ICH admissions. At low volume COVID-19 centers, there was no difference (-1.7%, [-2.0, -1.4]; p=0.27) in ICH admissions. In the tertile of high volume intracranial hemorrhage centers, 27/70 (39%) were high tertile COVID-19 centers. There was no observed decrease in ICH admissions at primary stroke centers (-3.2%, [-3.8, -2.7]; p=0.15) but a 5.1% ([-5.4, -4.8]; p<0.0001) decrease at comprehensive stroke centers (**Table 2**), with continental variation noted (**eTable 4**).

Intravenous Thrombolysis

There was a relative decline in intravenous thrombolysis, with 24,584 therapies in the pre-pandemic year compared to 23,077 during the pandemic year, representing a 6.1% absolute decrease ([-6.4,-5.8]; p<0.0001 n=239 sites); monthly mean (SE) volume decreased (7.5 (1.1) to 7.0 (1.1); p=0.006, n=244 sites). (**Figure, B**) There was a 7.1% ([6.8,8.2];p=0.02) increase in IVT at low volume IVT centers. For intermediate volume centers, there was no significant change (-3.1%, [-3.5,-2.7]; p=0.07), and for high volume centers, there was a 9.4% ([-9.8,-8.9];p<0.0001) relative decrease in IVT volume. The observed volume decrease was greater at higher volume COVID-19 centers (low vs. intermediate vs. high; p<0.0001). In the tertile of high volume IVT centers, 33/72 (46%) were high tertile COVID-19 centers. There was a larger relative decrease in IVT volumes at primary stroke centers than comprehensive stroke centers (-11.4% vs. -4.9%; p<0.0001) (**Table 3**) with continental variation (**eTable 5**).

Mechanical thrombectomy

There was no change in MT volume from the pre-pandemic to pandemic year (18,375 vs. 18,507, 0.7 ([0.6,0.9]; p=0.49, n=199 sites); monthly volume was also similar between the two epochs (6.2 (1.1) vs 6.3 (1.1); p=0.72, n=205 sites) (**Table 4, Figure, B**). Among all subgroups, the only difference was a 13.6% ([11.9,15.4]; p=0.001) relative increase at low MT volume centers (**Table 4**), with continental variation (**eTable 6**).

Rates of Concomitant Stroke with COVID-19 Admissions

Concomitant stroke diagnosis with COVID-19 admissions was reported by 218 centers. Overall, stroke diagnosis (any type) was present in 1.3% ([95%CI 1.31-1.38], 5,453/406,792) of COVID-19 admissions. There was continental variation: Africa 0.8% ([0.68-1.04], 87/10,321), Asia 1.6% ([1.52-1.75], 727/44,664), Oceania 0% ([0-1.11], 0/345), Europe 1.6% ([1.55-1.67], 2,689/166,692), North America 1.1% ([1.06-1.16], 1,688/152,654), and South America 0.8% (0.73-0.93], 262/32,116). (**Table 5**)

Concomitant SARS-CoV-2 infection with stroke admission was present in 2.9% ([95%CI, 2.82-2.97], 5,656/195,539) overall, with geographic variation: Africa 4.8% ([3.9-5.9], 87/1,802), Asia 1.5% ([1.37-1.58], 782/53,109), Oceania 0% ([0-0.08], 0/5,032), Europe 3.7% ([3.57-3.84], 2,811/75,993), North America 3.2% ([3.04-3.34], 1,714/53,730), South America 4.5% ([3.96-5.02], 262/5,873). (**Table 6**)

DISCUSSION:

In this cross-sectional study, after the onset of the COVID-19 pandemic, there were substantial decreases in ischemic stroke admissions (7.0%, [95%CI: 7.1,6,9]), ICH admissions (4.8%, [5.1,4.6]), and IVT use (6.1%, [6.4,5.8]) in the one-year of the pandemic compared to the year prior. However, there was no significant difference in the volume of MT between the pandemic and pre-pandemic year. As noted in our prior work with the first wave, among centers with high COVID-19 admission volumes, there was a greater decrease in stroke admission volumes compared to those with low COVID-19 admission volumes (6.6% vs. 11.0%; $p<0.0001$). These findings are consistent with recent national studies evaluating the impact of COVID-19 on stroke admissions during the second wave of the pandemic.[33]

We observed an overall relative decrease in ischemic stroke admission volume across 245 primary and comprehensive stroke centers worldwide. This trend was consistent across all prespecified subgroups. As hypothesized, centers with high COVID-19 volumes had greater decreases in stroke admission volume than those with low COVID-19 volumes. This may reflect a lack of capacity to accommodate stroke admissions at centers with high COVID-19 admissions or different stroke triage patterns during the COVID-19 pandemic. Comprehensive stroke centers experienced a smaller relative decrease in stroke admission volume than primary stroke centers (-6.8% vs. -8.2%).

Overall, ICH admission volumes decreased by 4.8% [5.1,4.6]. Of note, there was a 14.6% [13.2,16.1] increase in ICH volumes at low volume ICH centers. These results may indicate a partial shift in the volume of patients with ICH from intermediate and high-volume centers to

low volume centers, perhaps due to capacity limitations imposed by the high volume of COVID-19 patients at tertiary care centers.

The overall volume of IVT admissions decreased by 6.1% [6.4,5.8] during the pandemic year compared to the prior year, in line with our prior findings of decline in IVT volumes during the first wave of the pandemic.[7] This difference was driven by a large decrease in IVT at high volume centers (9.4%) while there was no significant difference at intermediate volume centers and a 7.1% [6.8,8.2%] increase in IVT at low volume centers.

No difference in overall mechanical thrombectomy volumes was observed in this study. The maintenance of mechanical thrombectomy volumes despite large decreases in overall stroke admission volumes suggests that the population of LVO patients was not significantly reduced through the pandemic year, concordant with early findings from the US Get With the Guidelines Stroke Registry.[21] Alternatively, any decline in mechanical thrombectomy volume related to the COVID-19 pandemic may have been offset by expanded indications for mechanical thrombectomy[34–41] or increased recruitment of cases by low volume centers.

Stroke represents an important complication in COVID-19 infection in an estimated 1.1% to 1.5% of COVID-19 admitted patients.[4,5,8] In our study, stroke was present in 1.3% of COVID-19 admitted patients, in alignment with previous studies. There were 2.9% of all hospitalized stroke patients with concomitant SARS-CoV-2 infection. While we cannot ascertain whether these cases were a direct complication of COVID-19 or an overlap of two conditions that are now

relatively common, we would favor the latter as it has become evident that stroke is a relatively rare complication of COVID-19.

Altogether, these results indicate a decrease in multiple measures of stroke volume and a shift of volumes towards previously lower volume centers but with the maintenance of mechanical thrombectomy volumes. The reduced volumes may suggest the reduced presentation of patients with mild stroke and TIA or changes in clinician decision-making, resulting in fewer admissions.[42,43] Alternatively, it is also possible that mild stroke patients were being triaged to the outpatient setting. Notably, mild strokes accounted for as many as 40% of all IVT cases and 10.7% of all EVT cases across 179 710 AIS patients in a US-based study.[44] This might explain the discrepancy in the relative declines amongst IVT and EVT observed in the current report. While the maintenance of mechanical thrombectomy volumes is reassuring as to the appropriate treatment of LVO patients, the shift seen in other volume measures toward lower volume centers is a trend to be noted. Previous studies have indicated that treatment at high volume centers is associated with better outcomes following stroke, ICH,[45] and mechanical thrombectomy.[46] In the Oceania region, where COVID-19 has been highly controlled, no differences were seen in stroke or intracranial hemorrhage admission volumes, and increases were seen in both IVT and thrombectomy volumes (e**Tables 5, 6**), further highlighting the effects of the pandemic. Additionally, COVID-19 was associated with 2.9% of stroke admissions in this study. Taken with recent studies suggesting that SARS-CoV-2 is likely to become endemic across the globe, this raises concern that SARS-CoV-2 may become an addition to other respiratory infections (influenza, mycoplasma pneumonia) known to trigger and present as a risk factor for stroke. Long term stroke metric and outcome data are important to evaluate whether these changes

persist beyond the pandemic. Some clinical practices for stroke diagnostic evaluation and management may be updated based on reorganization of stroke care during the pandemic.[47]

LIMITATIONS:

While we have robustly shown differences in population-level trends, our study is limited by the inability to characterize the reason for the changes in volumes over the subsequent waves of the pandemic. Inherent to our cross-sectional study design, we could not track changes on the patient level, and the observed population-level changes may be due to confounding factors. Future studies are important to understand patient-level factors influencing the observed trends in stroke volumes. Additionally, we had limited ability to study the effects of governmental policies (e.g., lockdowns) on stroke volumes since the COVID-19 pandemic has impacted every nation differently by timing and severity.

CONCLUSION:

During the first year of the COVID-19 pandemic, worldwide ischemic stroke admission, intracranial hemorrhage admission, and intravenous thrombolysis volumes were relatively decreased while there was no relative change in mechanical thrombectomy volumes. Further, shifts were seen in volumes toward lower-volume centers. A slight recovery in volumes was seen over the year compared to the initial months of the pandemic, but persistently low volumes raise concern that milder forms of a stroke may be untreated or are being redirected to the outpatient setting. Ongoing surveillance and additional future research is warranted to monitor stroke metrics[48–50] and long-term patient outcomes, ensure that public education measures are continued, and ensure patients continue to seek timely care for stroke.

WNL-2022-201299_etab ---http://links.lww.com/WNL/C442
WNL-2022-201299_coinvestigator_appendix1 --- http://links.lww.com/WNL/C443

REFERENCES

1. Elkind MSV, Boehme AK, Smith CJ, Meisel A, Buckwalter MS. Infection as a Stroke Risk Factor and Determinant of Outcome After Stroke. Stroke. 2020;51:3156–3168.

2. Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and Stroke in a New York Healthcare System. Stroke. 07 2020;51:2002–2011.

3. Ma A, Kase CS, Shoamanesh A, et al. Stroke and thromboprophylaxis in the era of COVID-19. J Stroke Cerebrovasc Dis. Elsevier BV; 2021;30:105392.

4. Ramos-Araque ME, Siegler JE, Ribo M, et al. Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry. BMC Neurol. bmcneurol.biomedcentral.com; 2021;21:43.

5. Siegler JE, Cardona P, Arenillas JF. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 multinational registry. J Stroke Cerebrovasc Dis [online serial]. journals.sagepub.com; Accessed at: https://journals.sagepub.com/doi/abs/10.1177/1747493020959216.

6. Nogueira RG, Abdalkader M, Qureshi MM, et al. Global impact of COVID-19 on stroke care. Int J Stroke. Epub 2021 Mar 29.:1747493021991652.

7. Nogueira RG, Qureshi MM, Abdalkader M, et al. Global Impact of COVID-19 on Stroke Care and IV Thrombolysis. Neurology. 2021;96:e2824–e2838.

8. Katsanos AH, Palaiodimou L, Zand R, et al. The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-Analysis. Ann Neurol. 2021;89:380–388.

9. Nguyen TN, Abdalkader M, Jovin TG, Nogueira RG. Mechanical thrombectomy in the era of the COVID-19 pandemic: emergency preparedness for neuroscience teams: a guidance statement from the Society of Vascular and Interventional Neurology. Stroke. 2020;51:1896–1901.

10. Jillella DV, Nahab F, Nguyen TN, et al. Delays in thrombolysis during COVID-19 are associated with worse neurological outcomes: the Society of Vascular and Interventional Neurology Multicenter Collaboration. J Neurol. 2022;269:603–608.

11. Nguyen TN, Jadhav AP, Dasenbrock HH, et al. Subarachnoid hemorrhage guidance in the era of the COVID-19 pandemic - An opinion to mitigate exposure and conserve personal protective equipment. J Stroke Cerebrovasc Dis. Elsevier; 2020;29:105010.

12. Abdalkader M, Sathya A, Malek AM, et al. Roadmap for Resuming Elective Neuroendovascular Procedures Following the First COVID-19 Surge. J Stroke Cerebrovasc Dis. 2020;29:105177.

13. Katsanos AH, Palaiodimou L, Zand R, et al. Changes in Stroke Hospital Care During the COVID-19

Pandemic: A Systematic Review and Meta-Analysis. Stroke. 2021;52:3651–3660.

14. Siegler JE, Heslin ME, Thau L, Smith A, Jovin TG. Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center. J Stroke Cerebrovasc Dis. 2020;29:104953.

15. Uchino K, Kolikonda MK, Brown D, et al. Decline in Stroke Presentations During COVID-19 Surge. Stroke. 08 2020;51:2544–2547.

16. Ghoreishi A, Arsang-Jang S, Sabaa-Ayoun Z, et al. Stroke Care Trends During COVID-19 Pandemic in Zanjan Province, Iran. From the CASCADE Initiative: Statistical Analysis Plan and Preliminary Results. J Stroke Cerebrovasc Dis. 2020;29:105321.

17. Kristoffersen ES, Jahr SH, Thommessen B, Rønning OM. Effect of COVID-19 pandemic on stroke admission rates in a Norwegian population. Acta Neurol Scand. 2020;142:632–636.

18. Raymaekers V, Demeestere J, Bellante F, et al. The impact of COVID-19 on acute stroke care in Belgium. Acta Neurol Belg. 2021;121:1251–1258.

19. Sedova P, Brown RD Jr, Bryndziar T, et al. Treat COVID-19, but Not Only COVID-19: Stroke Matters as Well. Cerebrovasc Dis. Epub 2021 Aug 11.:1–8.

20. Seiffert M, Brunner FJ, Remmel M, et al. Temporal trends in the presentation of cardiovascular and cerebrovascular emergencies during the COVID-19 pandemic in Germany: an analysis of health insurance claims. Clin Res Cardiol. 2020;109:1540–1548.

21. Srivastava PK, Zhang S, Xian Y, et al. Treatment and Outcomes of Patients With Ischemic Stroke During COVID-19: An Analysis From Get With The Guidelines-Stroke. Stroke. 2021;52:3225–3232.

22. Sacco S, Ricci S, Ornello R, et al. Reduced Admissions for Cerebrovascular Events During COVID-19 Outbreak in Italy. Stroke. 2020;51:3746–3750.

23. Katsouras C, Karapanayiotides T, Papafaklis M, et al. Greater decline of acute stroke admissions compared with acute coronary syndromes during COVID-19 outbreak in Greece: Cerebro/cardiovascular implications amidst a second wave surge. Eur J Neurol [online serial]. Epub 2020 Dec 8. Accessed at: https://www.ncbi.nlm.nih.gov/pubmed/33290619.

24. Nogueira RG, Qureshi MM, Abdalkader M, Martins SO et al. Global impact of COVID-19 on stroke care and intravenous thrombolysis. Neurology 2021;96:e2824–e2838.

25. Nguyen TN, Haussen DC, Qureshi MM, et al. Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic. Stroke Vasc Neurol. 2021;6:542–552.

26. Rana A, Nguyen TN, Siegler JE. Stroke and neurointervention in the COVID-19 pandemic: a narrative review. Expert Rev Med Devices. 2021;18:523–531.

27. Romoli M, Eusebi P, Forlivesi S, et al. Stroke network performance during the first COVID-19 pandemic stage: A meta-analysis based on stroke network models. Int J Stroke. journals.sagepub.com; 2021;16:771–783.

28. Siegler JE, Abdalkader M, Michel P, Nguyen TN. Therapeutic Trends of Cerebrovascular Disease

during the COVID-19 Pandemic and Future Perspectives. Journal of Stroke. 2022;24:179–188.

29. SVIN COVID-19 Global SAH Registry. Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up. J Neurol Neurosurg Psychiatry [online serial]. Epub 2022 Jul 28. Accessed at: http://dx.doi.org/10.1136/jnnp-2022-329200.

30. Timeline of first confirmed cases by country or territory. Accessed at: https://en.wikipedia.org/wiki/COVID-19_pandemic_by_country_and_territory#Timeline_of_first_confirmed_cases_by_country_or_territory.

31. Nguyen TN, Qureshi MM, Klein P, et al. Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality. Journal of Stroke. 2022;24:256–265.

32. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods [online]. Statistics in Medicine 1998. p. 857–872. Accessed at: http://dx.doi.org/10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e.

33. Katsouras C, Tsivgoulis G, Papafaklis M, et al. Persistent decline of hospitalizations for acute stroke and acute coronary syndrome during the second wave of the COVID-19 pandemic in Greece: collateral damage unaffected. Ther Adv Neurol Disord. 2021;14:17562864211029540.

34. Martins SO, Mont'Alverne F, Rebello LC, et al. Thrombectomy for Stroke in the Public Health Care System of Brazil. N Engl J Med. 382:2316–2326.

35. Nguyen TN, Abdalkader M, Nagel S, et al. Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion. JAMA Neurol [online serial]. Epub 2021 Nov 8. Accessed at: http://dx.doi.org/10.1001/jamaneurol.2021.4082.

36. Herweh C, Abdalkader M, Nguyen TN, et al. Mechanical Thrombectomy in Isolated Occlusion of the Proximal Posterior Cerebral Artery. Front Neurol. Frontiers Media SA; 2021;12:697348.

37. de Havenon A, Castonguay A, Nogueira R, et al. Prestroke Disability and Outcome After Thrombectomy for Emergent Anterior Circulation Large Vessel Occlusion Stroke. Neurology. 2021;97:e1914–e1919.

38. Berberich A, Finitsis S, Strambo D, et al. Endovascular therapy versus no endovascular therapy in patients receiving best medical management for acute isolated occlusion of the posterior cerebral artery: Systematic review and meta-analysis. Eur J Neurol [online serial]. Wiley Online Library; Epub 2022 May 19. Accessed at: https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.15410.

39. Campbell BCV, Nguyen TN. Advances in Stroke: Treatments-Interventional. Stroke. Ovid Technologies (Wolters Kluwer Health); 2022;53:264–267.

40. Mohammaden MH, Haussen DC, Al-Bayati AR, et al. Stenting and Angioplasty in Neurothrombectomy: Matched Analysis of Rescue Intracranial Stenting Versus Failed Thrombectomy. Stroke. 2022;53:2779–2788.

41. Nguyen TN, Raymond J, Nogueira RG, Fischer U, Siegler JE. The Problem of Restrictive

Thrombectomy Trial Eligibility Criteria. Stroke. 2022;53:2988–2990.

42. Demaerschalk BM. Where in the World Have All the Strokes Gone? Neurology. Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2021;96:1069–1070.

43. Ortega-Gutierrez S, Farooqui M, Zha A, et al. Decline in mild stroke presentations and intravenous thrombolysis during the COVID-19 pandemic: The Society of Vascular and Interventional Neurology Multicenter Collaboration. Clin Neurol Neurosurg. 2021;201:106436.

44. Saber H, Khatibi K, Szeder V, et al. Reperfusion Therapy Frequency and Outcomes in Mild Ischemic Stroke in the United States. Stroke. 2020;51:3241–3249.

45. McKinney JS, Cheng JQ, Rybinnik I, Kostis JB, Myocardial Infarction Data Acquisition System (MIDAS 22) Study Group. Comprehensive stroke centers may be associated with improved survival in hemorrhagic stroke. J Am Heart Assoc [online serial]. Ovid Technologies (Wolters Kluwer Health); 2015;4. Accessed at: https://www.ahajournals.org/doi/10.1161/JAHA.114.001448.

46. Gupta R, Horev A, Nguyen T, et al. Higher volume endovascular stroke centers have faster times to treatment, higher reperfusion rates and higher rates of good clinical outcomes. J Neurointerv Surg. 2013;5:294–297.

47. Bersano A, Kraemer M, Touzé E, et al. Stroke care during the COVID-19 pandemic: experience from three large European countries. Eur J Neurol. 2020;27:1794–1800.

48. Czap AL, Zha AM, Sebaugh J, et al. Endovascular thrombectomy time metrics in the era of COVID-19: observations from the Society of Vascular and Interventional Neurology Multicenter Collaboration. J Neurointerv Surg [online serial]. 2022;14. Accessed at: http://dx.doi.org/10.1136/neurintsurg-2020-017205.

49. Zha AM, Sharrief AZ, Czap AL, et al. Short□Term Outcomes of Acute Stroke During COVID□19 by Race and Ethnicity in the United States: The Society of Vascular and Interventional Neurology Multicenter Collaboration. Stroke: Vascular and Interventional Neurology. American Heart Association; 0:e000344.

50. Siegler JE, Ortega□Gutierrez S, Hester T, et al. Interaction of Ethnicity and Arrival Method on Thrombectomy Delay: The Society of Vascular and Interventional Neurology Collaboration. Stroke: Vascular and Interventional Neurology. American Heart Association; 2022;2:e000217.

Table 1. Ischemic stroke admissions overall and monthly volumes before and during the COVID-19 pandemic.

		Overall volume				Monthly volume*			
	N	n1	n2	Change	*P*	N	Before COVID-19	During COVID-19	*P*
				% (95% CI)			Adjusted Mean (SE)		
Overall	245	148,895	138,453	-7.0 (-7.1 - -6.9)	<0.0001	251	43.8 (4.0)	40.3 (3.9)	<0.0001
Hospital Ischemic stroke volume†									
Low	83	19,437	18,440	-5.1 (-5.5 - -4.8)	<0.0001	84	18.5 (1.1)	17.6 (1.2)	0.081
Intermediate	82	41,789	39,145	-6.3 (-6.6 - -6.1)	<0.0001	84	40.6 (1.9)	38.2 (2.0)	0.0003
High	80	87,669	80,868	-7.8 (-7.9 - -7.6)	<0.0001	83	84.4 (6.3)	77.4 (6.4)	<0.0001
Primary vs. Comprehensive stroke center‡									
Primary	68	26,141	24,007	-8.2 (-8.5 - -7.8)	<0.0001	70	28.7 (4.9)	26.5 (5.0)	0.058
Comprehensive	177	122,754	114,446	-6.8 (-6.9 - -6.6)	<0.0001	181	49.3 (6.7)	45.4 (6.6)	<0.0001
Hospital COVID-19 volume§									
Low	70	37,281	34,811	-6.6 (-6.9 - -6.4)	<0.0001	71	35.5 (6.1)	32.7 (6.0)	0.011
Intermediate	70	42,660	40,391	-5.3 (-5.5 - -5.1)	<0.0001	71	50.8 (7.2)	47.9 (7.1)	0.004
High	70	47,129	41,931	-11.0 (-11.3 - -10.8)	<0.0001	72	45.1 (6.7)	39.3 (6.5)	<0.0001

Abbreviations: N=number of hospitals; n1=number of admissions during twelve months before COVID-19 pandemic; n2= number of admissions during twelve months of the COVID-19 pandemic; CI=confidence interval; SE=standard error

*The monthly volume analysis is adjusted for the date of peak COVID-19 volume for each country, the start date of the second wave, and the continent

†*P*: Low vs Intermediate=<0.0001; Low vs High=<0.0001; Intermediate vs High=<0.0001

‡*P*: Primary vs. Comprehensive=<0.0001

§*P*: Low vs Intermediate=<0.0001; Low vs High=<0.0001; Intermediate vs High=<0.0001

Table 2. Intracerebral hemorrhage admissions overall and monthly volumes before and during the COVID-19 pandemic.

		Overall volume				Monthly volume*			
	N	n1	n2	Change	*P*	N	Before COVID-19	During COVID-19	*P*
				% (95% CI)			Adjusted Mean (SE)		
Overall	239	29,585	28,156	-4.8 (-5.1 - -4.6)	<0.0001	246	9.7 (1.1)	9.2 (1.1)	0.015
Hospital Intracerebral hemorrhage volume†									
Low	80	2,319	2,657	14.6 (13.2 - 16.1)	<0.0001	82	2.5 (0.27)	2.9 (0.30)	0.017
Intermediate	80	7,235	6,865	-5.1 (-5.6 - -4.6)	0.002	82	7.4 (0.51)	7.0 (0.52)	0.011
High	79	20,031	18,634	-7.0 (-7.3 - -6.6)	<0.0001	82	21.4 (2.9)	20.0 (2.7)	0.013
Primary vs. Comprehensive stroke center‡									
Primary	65	4,010	3,882	-3.2 (-3.8 - -2.7)	0.150	68	4.9 (0.99)	4.8 (0.98)	0.664
Comprehensive	174	25,575	24,274	-5.1 (-5.4 – 4.8)	<0.0001	178	11.0 (2.0)	10.3 (2.0)	0.014
Hospital COVID-19 volume§									
Low	68	8,434	8,292	-1.7 (-2.0 - -1.4)	0.272	69	8.5 (1.5)	8.3 (1.5)	0.478
Intermediate	70	7,229	6,939	-4.0 (-4.5 - -3.6)	0.015	71	7.4 (1.3)	7.1 (1.3)	0.184
High	69	10,772	9,727	-9.7 (-10.3 - -9.2)	<0.0001	71	12.1 (3.0)	10.8 (2.8)	0.044

Abbreviations: N=number of hospitals; n1=number of admissions during twelve months before COVID-19 pandemic; n2= number of admissions during twelve months of COVID-19 pandemic; CI=confidence interval; SE=standard error

*The monthly volume analysis is adjusted for the date of peak COVID-19 volume for each country, the start date of the second wave, and the continent

†*P*: Low vs Intermediate=N/A; Low vs High=N/A; Intermediate vs High=<0.0001

‡*P*: Primary vs. Comprehensive=<0.0001

§*P*: Low vs Intermediate=<0.0001; Low vs High=<0.0001; Intermediate vs High=<0.0001

Table 3. Intravenous thrombolysis overall and monthly volumes before and during the COVID-19 pandemic.

		Overall volume				Monthly volume*			
	N	n1	n2	Change	*P*	N	Before COVID-19	During COVID-19	*P*
				% (95% CI)			Adjusted Mean (SE)		
Overall	239	24,584	23,077	-6.1 (-6.4 - -5.8)	<0.0001	244	7.5 (1.1)	7.0 (1.1)	0.006
Hospital Intravenous thrombolysis volume†									
Low	80	2,222	2,379	7.1 (6.8- 8.2)	0.021	81	1.9 (0.33)	2.1 (0.35)	0.157
Intermediate	80	6,804	6,596	-3.1 (-3.5 - -2.7)	0.072	82	7.0 (0.23)	6.8 (0.32)	0.425
High	79	15,558	14,102	-9.4 (-9.8 - -8.9)	<0.0001	81	16.3 (1.3)	14.9 (1.3)	0.001
Primary vs. Comprehensive stroke center‡									
Primary	62	4,621	4,092	-11.4 (-12.4 - -10.6)	<0.0001	64	7.0 (1.4)	6.4 (1.3)	0.092
Comprehensive	177	19,963	18,985	-4.9 (-5.2 - -4.6)	<0.0001	180	7.8 (1.2)	7.4 (1.1)	0.030
Hospital COVID-19 volume§									
Low	68	5,710	5,651	-1.0 (-1.3 - -0.80)	0.580	69	5.0 (1.2)	5.0 (1.2)	0.810
Intermediate	70	7,347	6,897	-6.1 (-6.7 - -5.6)	0.0002	71	7.6 (1.3)	7.2 (1.3)	0.122
High	67	8,470	7,426	-12.3 (-13.1 - -11.7)	<0.0001	69	9.6 (0.95)	8.5 (0.85)	0.003

Abbreviations: N=number of hospitals; n1=number of admissions during twelve months before COVID-19 pandemic; n2= number of admissions during twelve months of COVID-19 pandemic; CI=confidence interval; SE=standard error

*The monthly volume analysis is adjusted for the date of peak COVID-19 volume for each country, the start date of the second wave, and the continent

†*P*: Low vs Intermediate=N/A; Low vs High=N/A; Intermediate vs High=<0.0001

‡*P*: Primary vs. Comprehensive=<0.0001

§*P*: Low vs Intermediate=<0.0001; Low vs High=<0.0001; Intermediate vs High=<0.0001

Table 4. Mechanical thrombectomy overall and monthly volumes before and during the COVID-19 pandemic.

		Overall volume				Monthly volume*			
	N	n1	n2	Change	*P*	N	Before COVID-19	During COVID-19	*P*
				% (95% CI)			Adjusted Mean (SE)		
Overall	199	18,375	18,507	0.7 (0.6 - 0.9)	0.492	205	6.2 (1.1)	6.3 (1.1)	0.715
Hospital Mechanical thrombectomy volume†									
Low	66	1,423	1,616	13.6 (11.9 - 15.4)	0.001	69	1.6 (0.24)	1.8 (0.28)	0.101
Intermediate	67	5,221	5,426	3.9 (3.4 - 4.5)	0.047	69	6.6 (0.27)	6.8 (0.32)	0.312
High	66	11,731	11,465	-2.3 (-2.6 - -2.0)	0.081	67	14.6 (1.2)	14.2 (1.2)	0.260
Primary vs. Comprehensive stroke center‡									
Primary	19	826	883	6.9 (5.4 - 8.8)	0.168	21	3.0 (1.0)	3.2 (1.1)	0.605
Comprehensive	180	17,549	17,624	0.4 (0.3 - 0.5)	0.689	184	6.5 (1.2)	6.6 (1.2)	0.844
Hospital COVID-19 volume§									
Low	56	4,076	4,043	-0.8 (-1.1 - -0.6)	0.714	57	5.3 (1.2)	5.2 (1.2)	0.830
Intermediate	51	4,705	4,817	2.4 (2.0 - 2.9)	0.251	54	6.9 (1.6)	7.1 (1.7)	0.601
High	63	6,771	6,720	-0.8 (-1.0 - -0.6)	0.661	64	5.6 (1.2)	5.6 (1.2)	0.770

Abbreviations: N=number of hospitals; n1=number of admissions during twelve months before COVID-19 pandemic; n2= number of admissions during twelve months of COVID-19 pandemic; CI=confidence interval; SE=standard error

*The monthly volume analysis is adjusted for the date of peak COVID-19 volume for each country, the start date of the second wave, and the continent

†*P*: Low vs Intermediate=<0.0001; Low vs High=<N/A; Intermediate vs High=N/A

‡*P*: Primary vs. Comprehensive=<0.0001

§*P*: Low vs Intermediate=N/A; Low vs High=1.0; Intermediate vs High=N/A

Table 5. Proportion of patients hospitalized with COVID-19 with concomitant diagnosis of stroke

	Number of Centers	COVID-19 with any stroke	COVID-19 Hospitalization	%	95% CI	
Overall	218	5,453	406,792	1.34	1.31	1.38
Asia	51	727	44,664	1.63	1.52	1.75
North America	55	1,688	152,654	1.11	1.06	1.16
Europe	90	2,689	166,692	1.61	1.55	1.67
South America	11	262	32,116	0.82	0.73	0.93
Oceania	6	0	345	0	0	1.11
Africa	5	87	10,321	0.84	0.68	1.04

Table 6. Rates of Concomitant COVID-19 with Stroke Hospitalizations

	Number of Centers	COVID-19 with any stroke	Stroke Hospitalization	%	95% CI	
Overall	225	5,656	195,539	2.89	2.82	2.97
Asia	54	782	53,109	1.47	1.37	1.58
North America	57	1,714	53,730	3.19	3.04	3.34
Europe	93	2,811	75,993	3.7	3.57	3.84
South America	11	262	5,873	4.46	3.96	5.02
Oceania	5	0	5,032	0	0	0.08
Africa	5	87	1,802	4.8	3.93	5.92

Figure 1. Monthly volume for ischemic stroke admissions, intracranial hemorrhage admissions, intravenous thrombolysis, mechanical thrombectomy, and COVID-19 admissions

Figure 1a. Monthly admission volume for ischemic stroke (blue), intracranial hemorrhage (red) and COVID-19 (yellow)
Figure 1b. Monthly volume for intravenous thrombolysis (orange), mechanical thrombectomy (blue) and COVID-19 (yellow)



Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events: One-Year Follow-up

Thanh N. Nguyen, Muhammad M Qureshi, Piers Klein, et al.

Neurology published online October 18, 2022
DOI 10.1212/WNL.0000000000201426